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Prostate cancer is the second most common cancer in the United States that affects men today. To 
better treat this disease accurate biomarkers and successful therapeutic treatments are needed. A 
novel approach to understand the mechanisms behind prostate cancer tumor formation lies in 
identifying dysregulated micro-RNAs (miRNAs), which are a class of small (18-24 nucleotides) 
non-coding RNAs that regulate gene expression posttranscriptionally by either inhibiting protein 
synthesis or signaling messenger-RNA for degradation. Multiple miRNAs were discovered in our 
highly tumorigenic and metastatic prostate cancer progression model M12 cell line compared to 
its weakly tumorigenic P69 parental cell line. Various analyses such as human panel analyses, 
single-miR analyses and patient tumor biopsy samples were analyzed to determine dysregulated 
miRNAs that contributed to the progression and metastasis of prostate cancer. Together with 
performing experiments to identify miRNAs, a de novo next generation sequencing approach was 
applied to identify miRNAs naturally present in biological fluids of normal and healthy subjects. 
Since, these miRNAs are highly dysregulated in many diseases, including cancer, they can act as
 
 
 
potential biomarkers or therapeutic targets to improve treatments for prostate cancer. Essential 
miRNAs studied for this research are miR-17-3p that is known to target the ErbB2 mRNA; miR-
299-5p that directly targets osteopontin (OPN), and miR-147b which directly targets many 
mRNAs, such as COL4A2, ALDH5A1, NDUFA4, SDHD, and IER5. A wide range of miRNAs 
were identified in six biological fluids: venous blood, menstrual blood, vaginal fluid, semen, 
saliva, and feces. There were some miRNAs that were common to all 6 body fluids, and some 
miRNAs that literature suggested could potentially be biomarkers or normalizers for body fluid 
characterization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: 
Introduction, background, and foundation of miRNA research 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1 Prostate cancer and its origin 
Over the past several years, research in the field of cancer has elevated exponentially. 
Cancer is a heterogeneous disease that is a result of multiple gene mutations, aberrant gene 
expressions, and microRNA (miRNA) dysregulation [4, 5].  A host of mutational events in DNA, 
combine to dysregulate multiple signaling pathways. Bioinformatics analyses have elucidated a 
dozen more signaling pathways, which impinge tumorigenesis, and a range of mutations that differ 
even in similar tumors [1]. Furthermore, high-throughput sequencing data have revealed that there 
are many more point mutations, translocations, amplifications, and deletions that heavily 
contribute to cancer development [2, 3].  
 In the U.S. one of the most commonly diagnosed cancers, and a leading cause of cancer 
death in men is prostate cancer [6]. Prostate cancer develops in the prostate gland, which forms a 
part of the male reproductive system. The main function of this gland is to produce seminal fluid, 
which is alkaline in nature, and produced to protect and enrich the sperm, thereby enhancing its 
survival for an elongated period of time [7]. All prostate related diseases, both benign and 
malignant, stem from this walnut-shaped gland located at the base of a man’s bladder. Normal 
prostate epithelium is composed of basal and luminal cells. In prostate cancer, the luminal and 
basal cell arrangement is disrupted and a loss of basal cells is observed. The expansion of luminal 
cells expressing prostate-specific antigen (PSA) is associated with the origin of human prostate 
cancer. Activation of the P13K pathway due to the loss of PTEN, is also frequently observed in 
human prostate cancer. Although luminal cells, commonly being the origin of prostate cancer, are 
used as therapeutic targets, now basal cells are showing potential as therapeutic targets, due to the 
presence of prostatic stem cells in the basal epithelium compartment [8].  
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 A variety of genetic and epigenetic factors such as age, race, heredity, diet, sexual, and 
physical activity contribute to the development of prostate tumors. Age especially, is an important 
factor. Young and healthy men have a small prostate while older men, around the age of fifty, tend 
to have an enlarged prostate. The increase in size of the prostate is due to male hormones called 
androgens, such as testosterones [9]. The growth of the prostate can either be classified as benign 
or malignant. Benign cases are often referred to as benign prostatic hyperplasia (BPH), where the 
prostate enlarges and presses on the urethra, resulting in irregular flow of urine. Since, these are 
benign cases, their overgrowth does not invade other tissues or organs. In malignant cases, the 
cells invade and damage nearby tissues, eventually leading to metastasis to bone and brain [10].  
1.2 Common occurrences of prostate cancer 
According to the American Cancer Society, in the year of 2014, a total of 233,000 new 
prostate cancer cases are being estimated while 29,480 deaths are being predicted. It is a disease 
that affects approximately 1 out of 6 men in their lifetime [11].  It has been estimated that every 
2.3 minutes, a new case of prostate cancer occurs, while every 16 minutes a man dies from prostate 
cancer. In fact more than 2.5 million American men are currently living with prostate cancer. When 
compared to other cancers it has been estimated that a man is 35% more likely to be diagnosed 
with prostate cancer than a woman is to be diagnosed with breast cancer. African American men 
are 56% more susceptible to prostate cancer and 2.5 times more likely to die from this disease than 
the Caucasian men. Men, aged 65 or above, with a family history of prostate cancer are twice as 
likely to develop this disease [10]. 
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1.3 Screening of prostate cancer 
When considering the risks of prostate cancer, several factors are taken into account such 
as, the grade of cancer, (Gleason score), the PSA level, and the stage of cancer- basically how 
large is the tumor is and has it metastasized [12].  
The Gleason Score enables physicians to grade the prostate cancer. It is considered as one 
of the most reliable methods for estimating the aggressiveness of prostate cancer. A Gleason score 
is the sum of two scores, where the primary Gleason grade is added to the secondary Gleason grade 
to produce a score. These grades range from 1-5; where a grade of 1, basically resembles the 
normal prostate whereas a grade of 5 is considered an extreme case of cancer. The Gleason sum 
ranges from 2-10 where an extreme case of prostate cancer is denoted by the score of 10 [12].  
The PSA is a protein produced by both normal and prostate cancer cells. In order to detect 
signs of prostate cancer, the PSA test measures the level of PSA in a man’s blood. Results are 
usually reported per milliliter of blood. PSA levels under 4 ng/ml are considered healthy for men 
and as the PSA level rises the chances of having prostate cancer also rises. Usually, a PSA level 
less than 10 is considered a low risk, while 10-20 is considered an intermediate risk, and >20 is 
considered high risk [13]. Identifying PSA levels maybe a good initial step for detecting the 
occurrences of prostate cancer, but it is not very specific. Sometimes men with even a high PSA 
level do not have cancer and this is because PSA levels can rise due to variety of benign conditions 
such as inflammation of the prostate, BPH, or prostatitis of prostate cancer. Therefore, PSA testing 
alone is not sufficient to detect prostate cancer; hence a digital rectal exam (DRE) should be used 
in combination with PSA monitoring for diagnosing the disease [13].  
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The stage of cancer is determined based on the size of the tumor and how much it has 
metastasized. Typically, these stages are expressed as the T, N, and M score, and are collectively 
referred to as the TNM system for staging prostate cancer. T plus a number (0-4) is used to 
determine the location of tumor, where a score of T0/T1 indicates a tiny to no tumor and is only 
picked up by PSA testing or sometimes not picked up by any sort of imaging. A Score of T4 
indicates the tumor is fixed or it is beginning to invade the nearby tissues or organs, other than the 
seminal vesicles. N stands for the lymph nodes and it ranges from 0-1, where N0 indicates that 
cancer has not spread to the lymph nodes, and N1 indicates it has. M in the TNM system indicates 
the metastasis of tumor to other parts of the body such as the lungs or bones. It ranges from 0-1, 
where M0 indicates the disease has not spread, while M1 indicates it has begun to spread beyond 
the lymph nodes (Figure 1-1) [10, 13, 14].  
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Figure 1-1: The TNM system of prostate cancer. Stage T1 indicates clinically the tumor was 
not found by examination or by the use of imaging such as a transrectal ultrasound. Stage T2 
indicates a tumor found confined to the prostate, in either one or both lobes by digital rectal exam 
(DRE) or transrectal ultrasound. Stage T3 indicates the tumor has extended through the capsule 
surrounding the prostate and may have begun to spread into the seminal vesicles. Stage T4 
indicates the tumor has metastasized to nearby tissues or organs, other than seminal vesicles, such 
as the urethral sphincter. Stage N+ indicates that the lymph nodes show incidence of prostate 
cancer, while stage M+ indicates that cancer has slowly begun to spread to distant organs [12-14].  
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1.4 Treatments for prostate cancer 
Prognosis of prostate cancer depends on whether the disease is non-metastatic or 
metastatic. For non-metastatic disease age, clinical stage, Gleason score, PSA level, and co-
morbidity are important factors. If prostate cancer is discovered at an early stage, the majority of 
the times it can be cured. For metastatic cases age, site of metastases, weight loss, hemoglobin 
level and androgen dependence are important factors. Once the tumor extends beyond the prostate 
gland, it becomes fatal and survival rates drop, hence currently for metastatic cases, no curative 
therapy exists [15].  
Treatments are based on the type of cancer and the aforementioned factors, including life 
expectancy and personal preference. For an unfit elderly man with non-metastatic prostate cancer 
such as T1 or T2 tumors the patient is more likely to die due to other reasons than the cancer itself. 
For patients whose life expectancy is less than 10 years, their personal preference may include no 
treatment. Otherwise, radiotherapy or brachytherapy are often suggested for the elderly. For a 
healthy elderly or a younger adult with non-metastatic prostate cancer, the life expectancy is often 
more than 10 years. In this case often radical prostatectomy, external beam radiotherapy, or 
brachytherapy are suggested in an attempt to eradicate tumor. For cases where prostate cancer has 
locally invaded the seminal vesicles, radiotherapy or hormonal therapy is recommended. Patients 
who have been newly diagnosed with metastatic prostate cancer, together with radical 
prostatectomy undergo androgen deprivation and hormonal therapy. The optimal form of 
hormonal therapy is orchiectomy, which is removal of one or both testicles, gets rid of almost 90% 
of circulating androgens and the remaining 10% is produced by the adrenal glands [15].    
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Generally, within a few years of initial treatment, the tumor re-occurs in 15-30% of prostate 
cancer patients, eventually leading them to androgen deprivation therapy. This therapy has a higher 
success rate than other therapies, usually 70-80% of patients respond to it positively; however, it 
is only effective for patients with androgen-dependent prostate cancer. In a normal prostate cell 
and in the androgen-dependent prostate tumors, testosterone binds to the androgen receptor, which 
instigates the production of androgen and promotes cell growth. As tumor progresses to later 
stages, it becomes androgen-independent and fails to respond to the androgen deprivation therapy 
[17].  
There is an ongoing research on how the androgen receptors are able to promote growth in 
the absence of testosterone. Studies have shown that 50% of androgen-independent tumors contain 
point mutations in the androgen receptor gene. Hence, there are speculations, that these point 
mutations play a role in tumorigenesis [17, 18].  
Although there is chemotherapy, differential therapy, and numerous forms of hormonal 
therapy to alleviate the progression of prostate cancer, these are temporary and provide relief for 
only a short period of time. Serving to either slow down progression, or if the prostate cancer is in 
its early stage, attempt to eradicate cancer cells. To overcome the shortcomings of these therapies 
further research on the growth of cancer, the nature of the tumor and the mechanism behind its 
formation, must be elucidated.  
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1.5 Identifying biomarkers of prostate cancer 
Prostate cancer is highly heterogeneous in nature and multiple gene mutations play an 
important role in tumor progression. Lately, studies have revealed that apart from essentially 
identifying genes that promote tumor progression, protein and RNA also contribute to tumor 
progression and can potentially serve as biomarkers for this disease [16]. In fact, much of the 
research is currently being focused on microRNAs (miRNAs, miRs), which are small non-coding 
RNAs that influence the expression of a gene post-transcriptionally, either by inhibiting translation 
or targeting the transcribed messengerRNA (mRNA) for degradation. 
1.6 Micro-RNAs and their role in oncogenesis 
 Micro-RNAs are single stranded non-coding RNAs, 18-24 nucleotide (nt) in length, that 
post-transcriptionally regulate gene expression either by inhibiting translation or marking a mRNA 
for degradation. It has been estimated that miRNAs modulate almost 30-60% of protein coding 
genes [19]. Along with that they are also involved in the regulation of a variety of biological 
processes such as cell cycle differentiation, development, metabolism, cell proliferation, apoptosis, 
response to stress, as well as human diseases including diabetes, immunological or 
neurodegenerative disorders, and cancer [20, 21].  
MiRNAs were first discovered in 1993 in the nematode Caenorhabditis elegans [22]. Lee 
et al. discovered that the gene lin-4, which was an essential gene for C.elegans post-embryonic 
development, did not code for any protein, but was instead transcribed into a 22-nucleotide RNA 
molecule, which was able to inhibit the expression of the lin-14 mRNA by directly targeting its 3’ 
untranslated region (3'-UTR) [23].  Another case of RNA discovery was of the let-7 small RNA 
that was also involved in the developmental timing of C. elegans. When it was sequenced, it was 
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found to be highly conserved in a variety of organisms, which suggested that these small RNAs 
possibly play an important role in regulating gene expression outside of C. elegans. Soon, many 
miRNAs were discovered in worms, flies and mammalian genomes [24].  
The role of miRNAs is critical in tumor development as they regulate the cellular processes 
of oncogenes or tumor suppressor genes [26]. They are frequently located in cancer-related 
genomic regions such as regions of amplification, fragile sites, or common break point regions on 
or near oncogenes or tumor suppressor genes. Oncogenes are consistently observed to be up-
regulated in tumor verses normal tissue, whereas tumor suppressor genes are consistently down-
regulated in tumor versus normal tissue. In a given cancer miRNAs are either known to act as an 
oncomiR, where it gets overexpressed, or tumor suppressors, where its expression is lost. Due to 
miRNA dysregulation of miRNAs, increased expression of oncomiRs contributes to oncogenesis, 
while loss of tumor suppressors can also result in increased oncogenesis. Whether tumor 
suppressors are lost or oncormiRs overexpressed, the end result is cell growth, proliferation, tumor 
progression and ultimately metastasis [19, 26-27]. 
1.7 Biogenesis of miRNAs 
MiRNA genes are evolutionarily conserved across species and are potentially located either 
within introns or exons of protein coding genes or in the intergenic regions. These small non-
coding RNAs are transcribed in the nucleus by RNA polymerase II or sometimes RNA polymerase 
III into larger RNA precursors as primary-miRNAs (pri-miRNAs), which are often several 
kilobases long. These pri-miRNAs are then capped (MGpppG) and polyadenalated (AAAAA) [19] 
and further processed by the RNAse III enzyme Drosha and its co-factor DGCR8/Pasha, to 
generate an ~70 nucleotides long premature-miRNA (pre-miRNA). This pre-miRNA folds into a 
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stem-loop structure and gets exported from the nucleus into cytoplasm by a GTP-dependent 
exportin 5 transporter. Pre-miRNA is further processed by an RNAse III enzyme called Dicer, 
which together with its cofactor TRBP snips off the loop and releases a double stranded RNA 
duplex approximately 18-24 nts long. This double stranded RNA is then incorporated into the 
miRNA-associated multiprotein RNA-induced silencing complex (RISC) that includes the 
Argonaute proteins to help select the single stranded mature miRNA. Together with the mature 
miRNA bound within the RISC complex, mRNAs are targeted either for inhibition by blocking 
the translation of mRNA into proteins or for mRNA degradation. The first 5-7 bases on the 5’ end, 
also known as the “seed region” of the miRNA, are known to be required for binding to the 
complementary sequences of their target mRNA (Figure 1-2) [19, 28].  
The inhibition or destruction of an mRNA depends on the amount of sequence match 
between the miRNA and mRNA. When the miRNA matches perfectly with the mRNA, the result 
is degradation of the mRNA by cleavage between base 10 and 11 of the miRNA as well as the 
complementary region of the mRNA target. However, when only a few nucleotides match the 
result is inhibition of mRNA translation. The miRNA’s ability to bind to its target mRNA either 
perfectly or imperfectly enables it to act as a final modulator of protein expression. Alterations in 
normal expression patterns can contribute to cancer. Since cancer can result from the improper 
expression of a disordered genome where abnormal cells can grow uncontrollably, and metastasize 
to other parts of the body, miRNAs, are known to play a critical role in carcinogenesis and tumor 
progression. Bioinformatics data have shown that a microRNA can target many mRNAs as well 
as one mRNA can be targeted by many miRNAs [29].  
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Figure 1-2: MicroRNA biogenesis. (1): miRNA gene is being transcribed by RNA polymerase 
II into pri-miRNA of variable size, which is further cleaved by the RNAse III called Drosha with 
DGcR8, to produce a hairpin precursor form called pre-miRNA, which is approximately 70 nt 
long. (2): Pre-miRNA is exported from the nucleus into the cytoplasm by exportin 5 and further 
snipped off at the loop by another RNase III enzyme the Dicer. (3): TRBP complex generating a 
miRNA duplex of 18-24 nt in length. One strand is selected by the multiprotein RNA-induced 
silencing complex (RISC) by an unknown mechanism. (4): The mature miRNA depending on the 
complementary match to its mRNA, leads RISC to either inhibit mRNA’s translation or 
completely degrade the mRNA [19].  
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1.8 Nomenclature of miRNAs: 
For a given miRNA named “hsa-miR-147b”; the “hsa” refers to the species, in this case 
Homo sapiens miRNA, “miR” refers to the miRNA precursor, “147” refers to the 147th family that 
was named, and “147b” refers to its relativity to other miRNAs within the 147th family. For 
example, there must be at least one other family member as hsa-mir-147a. Other small letters such 
as from c-h refer to other family members, which all share the same "seed sequence" and differ by 
at most 1-2 nucleotides outside of the crucial seed region, hence they are included in the same 
miRNA family. Family members exhibit tissue-specific expression so various tissues/cell-types 
will differ in which family members are expressed. If a given name is “hsa-mir-299-3p” or “hsa-
mir-299-5p”, the same naming process applies till the 299th part; however, the 3p and 5p refers to 
the mature miRNA strand from either 3’ and 5’ end of the precursor, which means that hsa-mir-
299-3p was produced from the 3’ end of the mature miRNA, and hsa-mir-299-5p was produced 
from the 5’ end of the mature miRNA [25].  
1.9 Research objectives, previous works, and models used: 
The objective of our laboratory’s research is to identify key miRNAs, the dysregulation of 
which can contribute to prostate tumor progression. Dysregulated miRNAs that are involved in 
tumorigenesis can cause a variety of expression differences contributing to cancer development. 
In-vivo, in-vitro, and in-silico methods have been applied for miRNA identification purposes. 
Moreover, we seek the identification of miRNAs that can be used as biomarkers for prostate cancer 
identification, staging, and treatment. 
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1.9.1 Prostate cancer progression model M12 cell line: 
To investigate the progression of prostate cancer and to study the overall cellular behavior 
of a unique prostate cancer cell line the P69 cell line was developed. This cell line was developed 
from human non-neoplastic prostate epithelial cells isolated from a 63 year old African American 
male and immortalized with the simian virus 40 (SV40) large T antigen gene that inactivates the 
cellular break, the retinoblastoma protein (Rb). The P69s are poorly tumorigenic and non-
metastatic. A highly tumorigenic cell line was developed from the P69s by subcutaneously 
injecting in male athymic nude mice. Out of the eighteen mice that were injected only two mice 
developed tumors. After two successive rounds of such injections, a variant cell line, called the 
M2182 cell line, was developed. At each successive round of injections the tumors grew bigger 
and faster. On the third round of injections, another new cell line, called the M12 cell line was 
derived. Upon subcutaneous, intraperitoneal, and intraprostatic injections into the prostate it was 
found that the M12 cell line was not only highly tumorigenic, but it easily metastasized to multiple 
secondary sites in the animal such as the diaphragm, lung, and mesentery. Within the prostate field 
this is unique as all other prostate cell lines are unable on their own to escape from the confines of 
the prostate making the M12 cell line highly useful. In conclusion the P69, M2182, and the M12 
cell lines are tumorigenic models used to study prostate cancer (Figure 1-3) [30].  
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Figure 1-3: Development of the M12 cell line from the P69 cell line: Human prostate epithelial 
cells were immortalized with SV40 large T antigen and injected into athymic nude mouse. A series 
of injections were carried out in-vivo for selection process. During the first round of injection, the 
M1929 cell line developed, which was poorly tumorigenic and non-metastatic. From the second 
round of injection the M2182 cell line developed, which was fairly tumorigenic, but still not 
metastatic. Finally, from the third round of injections the M12 cell line was obtained which was 
highly tumorigenic and very metastatic when injected orthotopically.  
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1.9.2 Other prostate cancer cell lines: 
Three other sets of tissue culture cell lines used by researchers and our laboratory, to study 
the overall progression of prostate cancer are as follows: the Dunning-145 (DU-145), LNCaP, and 
PC3 cell lines. The first prostate cancer cell line to be developed was DU-145 cell line. This cell 
line was derived from a metastatic tumor excised from the brain of a 69 year old white male with 
prostate cancer. The LNCaP cell line was developed from a biopsy of a lymph node metastases 
from a 50 year old white male with prostate cancer. There are more than 60 sublines for this cell 
line, and the parental cell line expresses both the normal androgen receptor (AR) mRNA and 
protein. The PC3 cell line was developed from a lumbar vertebra metastasis from a 62 year old 
white male with prostate cancer. There are a total of 11 sublines for this cell line, some express the 
AR gene, and some do not [31].  
1.9.3 Identification of dysregulated miRNAs through the P69-M12 model cell lines 
Previous work performed in the laboratory revealed that miR-17-3p, a miRNA found on 
chromosome 19, to be down-regulated in the M12 cell line relative to the P69 cell line. This loss 
contributed to the expression of vimentin mRNA, which encodes for an intermediate filament 
protein up-regulated in the M12 compared to the P69 cell line. The high expression of vimentin 
was further reversed by stably transforming the M12 cell line with a plasmid vector expressing 
miR-17-3p, known as the M12+miR-17-3p cell line. The reduced expression of vimentin in the 
M12+miR-17-3p cell line indicated that miR-17-3p may potentially be binding to the 3’UTR of 
vimentin mRNA (Figure 1-4) [32].  Similarly, miR-125b was identified as a tumor suppressor due 
to a loss of expression observed in the M12 versus P69 cell line. A reduction in migration and 
invasiveness was observed when miR-125b was restored in the M12 cell line through stable 
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transformation, to generate the M12+miR-125b cell line. The mRNAs targets for miR-125b are 
ErbB2 & 3, which are found to be up-regulated in cancer [33]. 
 
 
 
 
 
 
 
 
 
 
Figure 1-4: Previous results showed that miR-17-3p targets vimentin. A- A gain of expression 
was observed for vimentin mRNA in the M12 cell line. B- Reduced expression of miR-17-3p 
observed in the M12 cell line versus the P69 cell line. C- Stable restoration of miR-17-3p in the 
M12 cell line (M12+miR-17-3p) resulted in a substantial decrease in vimentin levels.                     
(Adapted from Zhang et al. [32]).  
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1.10 Selection of miRNAs through screening processes 
The reduced expression of vimentin mRNA observed due to targeting by miR-17-3p, 
sparked an interest in miRNAs in our laboratory. Since then we have continued to search for 
additional miRNAs that could serve as oncomiRs or tumor suppressors driving prostate cancer. 
Together with this goal, we are also interested in identifying potential mRNA targets for these 
miRNAs, the differential expression of which contributes to the cellular behavior and mechanisms 
of prostate cancer progression in our model M12 cell line.   
 In order to identify important miRNAs in the progression model M12 cell line, a series of 
analyses were performed as follows; (1) microarray panels consisting of a total of 736 miRNAs 
were analyzed followed by, (2) Single-miR confirmatory analyses followed by, (3) miRNA 
expression analyses in additional prostate cancer cell lines, and finally, (4) analyzing dysregulated 
miRNAs through laser-capture microdissection (LCM) of benign, stromal, and tumor tissue from 
human patient biopsies [34].   
The entire credit for conducting analyses to select important miRNAs in prostate cancer goes to 
Drs. Sarah Seashols, William Budd, and Zendra Zehner. The order in which the names are 
listed by no means indicate the level of effort put into this project.  
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(1): Of a human panel of 736 miRNAs, the expression levels of miRNAs dysregulated in the P69 
versus M12 cell line were determined via Reverse Transcriptase-quantitative Polymerase Chain 
Reaction (RT-qPCR). This analyses determined miRNAs that were overexpressed (OncomiRs) or 
lost (Tumor suppressors) between the progression of the "normal" P69 to its highly 
tumorigenic/metastatic variant, M12. 
Results: Out of the 736 miRNAs analyzed, 231 miRNAs were found to be oncomiRs exhibiting a 
≥2 fold increase in the M12 vs. P69 cell lines. Conversely, 150 miRNAs exhibited a ≤ 0.5 fold 
decrease and were labeled as potential tumor suppressors. The remaining 355 miRNAs exhibited 
no significant change in expression (Figure 1-5).  
 
 
 
 
 
 
 
Figure 1-5 Human panel analyses of miRNA expression in P69 vs. M12 cell lines. Two human panel 
analyses were performed. Panel 1 was performed using 20 and 50 ng of RNA. Panel II was performed using 
50ng of RNA. The global mean was used to normalize the data and a fold difference was calculated. Fold 
expressions greater than 1 indicated high expressions of miRNA and lower than 1 indicated low expressions 
of miRNA, in the M12 cell line relative to the P69 cell line. (Adapted from Seashols [Dissertation] [34]) 
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MiRNAs chosen for confirmatory single miR analyses were not selected based not only on fold 
differences observed between the comparison of P69 to M12, but literature searches and 
bioinformatic tools were also incorporated to further confirm the selection. Furthermore, the 
miRNAs selected were a collection of both oncomiRs and tumor suppressors that showed 
relevance in prostate cancer.  
(2): Single-miR analyses, of selected miRNAs as seen in Table 1-1, were conducted through RT-
qPCR in RNA extracted from the M12 and P69 cell lines to confirm those trends exhibited in the 
human panel analyses. 
Results: Most of the miRNAs were confirmed, but not all. MiRs-622, -221, and -299-3p were 
drastically different from the human panel analyses. The differences between panel analyses and 
single-miR analyses may be due to normalization process. The human panel data was normalized 
to the global mean whereas the single-miR data was normalized to RNU48. Although minor 
differences are anticipated due to differences in normalizations, but major differences should not 
account to different normalizations (Figure 1-6).  
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Table 1-1: MiRNA selected for single-miR analyses.                                                                                                
The highlighted miRNAs were selected for further studies in this thesis (MiRNAs and values for 
expression difference values adapted from Seashols [Dissertation] [34]). 
MiRNA 
Expression difference 
(M12 vs P69) 
9 6.68 
144 0.374 
 133a 37.91 
 133b 38.93 
 146a 0.459 
 147b 201.4 
 199a-3p 6.43 
221 0.783 
 299-3p 11.37 
 299-5p 0.02 
147 27.9 
488 0.526 
622 147.7 
 127-3p 0.002 
 127-5p 0.344 
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Figure 1-6: Comparing the expressions of miRNAs between the human panel and single-miR 
confirmatory analyses. The panel analyses was normalized against the global mean and single-
miR analyses was normalized against RNU48. Fold expression values of M12 cell line was set 
relative to the P69 cell line. Each sample was analyzed in triplicate. The ones outlined in red are 
miRNAs being studied for this thesis. The expression of miR-147b was consistent between the 
panel and single-miR analyses. MiR-299-3p was overexpressed in the panel analyses, but lost 
expression in the single-miR analyses. Loss of expression was observed for miR-299-5p in the 
panel analyses, but a value for single-miR analyses was not obtained due to a failed normalization 
expression value for the normalization standard to RNU48 (Adapted from Seashols [Dissertation] 
[34]).  
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(3): For additional confirmation, miRNAs that act as oncomiRs or tumor suppressors in both 
human panel analyses and single-miR analyses, were further evaluated in additional prostate cell 
lines, as following; PC3; DU-145 which is moderately metastatic; F6, a poorly tumorigenic, non-
metastatic prostate cell line, obtained after re-introducing chromosome 19 into the M12 cell line; 
M2182, a moderately tumorigenic, non-metastatic cell line derived after second round of injections 
into the mouse, before development of the M12 cell line (Figure 1-7). Such comparisons permit 
the identification of miRNAs that behave identically in other relevant prostate cell lines, plus 
confirms which miRNA might be the most responsible for driving prostate tumorigenesis. 
(4): Solid tumors like prostate are highly heterogeneous both in cell-type and stage of tumor 
development. In one tumor it is possible to find various stages of prostate cancer cells. These 
prostate cancer stages can be scored by the pathologist with a Gleason score ranging from 3-7 with 
an increase in number indicative of a higher staged cancer. Laser-capture microdissection (LCM) 
was used to extract RNA from formalin-fixed paraffin embedded (FFPE) or frozen tissue retrieved 
from prostatectomies to confirm via RT-PCR which miRNAs selected from the above analyses 
are truly dysregulated as normal glandular epithelial progresses to highly tumorigenic/metastatic 
cancer.  
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Results: Although the expression of some miRNAs varied from the results obtained above with 
human prostate cell lines, the expression of a few miRNAs remained consistent within the limited 
number (5) of patient biopsy samples available for LCM analysis. MiR-9 and miR-147b constantly 
came out to be as oncomiRs, whereas miR-299-3p, miR-199a-3p were tagged as tumor suppressors 
(Figure 1-8).  
Figure 1-7: Measuring expressions of oncomiRs, and tumor suppressors in prostate cancer 
cell lines. MiRNAs levels were normalized to RNU48 and expression fold values of M12 are 
relative to the P69 cell line. Each sample was analyzed in triplicates. Those miRNAs outlined in 
red are being further studied in this thesis. MiR-147b is consistent in its expression, hence can be 
classified as an oncomiR. Reduced expression was observed for miR-299-3p in the M12, and F6 
cell lines. No expression value was reported for miR-299-5p in the M12 cell line due to 
normalization discrepancy in RNU48. However, reduced expression of this miRNA was observed 
in other cell lines (Adapted from Seashols [Dissertation] [34]).   
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Figure 1-8: Expressions of miRNAs observed in the laser capture microdissected tumor 
tissue samples. MiRNA levels were normalized to RNU48 and fold expression values were 
relative to the benign tissue of the same patient. MiR-147b remained consistent in its expression 
acting as an oncomiR. MiR-299-3p has remained consistent in its expression acting as a tumor 
suppressor. MiR-299-5p is also observed as an oncomiR in the patient tumor samples.                                            
(Adapted from Seashols [Dissertation] [34])  
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1.11 The purpose of this thesis: 
 Identification of key oncomiRs or tumor suppressor miRNAs and their mRNA targets in 
prostate cancer through in-vitro and in-silico approaches.  
The majority of work in the Zehner laboratory is devoted to identifying potential miRNAs 
that play an essential role in the progression of prostate cancer, by disrupting the cellular behavior 
to enhance proliferation, migration and invasiveness. Each chapter in this thesis presents an 
evaluation of miRNAs that were either highly dysregulated from cell lines to patient tumor biopsy 
samples, or showed great potential as key regulators of prostate cancer, or miRNAs that showed a 
direct connection between prostate cancer progression and the targets they prefer to bind. One of 
the chapters also presents an in-silico evaluation of miRNAs observed in the body fluids of normal 
and healthy people. 
Chapter 2:   
The work in Chapter 2 consists of determining which of the three potential miR-17-3p 
binding sites predicted in the 3’UTR of ErbB2, is/are most valuable for inhibiting the expression 
of ErbB2.  
Chapter 3: 
The work in Chapter 3 consists of determining potential mRNA targets for miR-299-5p. 
This miRNA was shown to be highly dysregulated in miRNA screen analyses and in the analyses 
of patient biopsy samples. Due to high variation observed in its expression, it became important to 
investigate the effects of miR-299-5p in prostate cancer.  
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Chapter 4: 
The work in Chapter 4 consists of finding relevant mRNA targets for miR-147b, an 
oncomiR. MiR-147b has stayed consistent in its expression from cell line analyses to patient tumor 
biopsy sample analyses. However, scarce research has been performed on this miRNA. Due to its 
consistent nature as an oncomiR, we propose that this miRNA is essential for prostate cancer and 
finding its mRNA target(s) is important.   
Chapter 5: 
An in-silico approach was applied to identify conserved or abundant miRNAs in body 
fluids obtained from normal healthy people. The idea behind this research is that miRNA screen 
analyses are limited in their approach to identify all miRNAs present in prostate cancer tumor, 
however next generation sequencing gets rid of this limitation and can detect all miRNAs present 
in the tumor. We initiated the body fluids project with normal and healthy body fluids because, it 
is essential to first determine which miRNAs are prominent in normal body fluids and then 
determine/compare which miRNAs were either lost or gained in body fluids from patients.  
1.11.1: In conclusion of this thesis (Chapter 6): 
The work performed for this thesis culminates with an overall analyses that miRNAs are 
diverse in their nature, and depending on each cell type or tissue they are either expressed as 
oncomiRs or as tumor suppressors. This was the case in prostate cancer as well, where out of the 
3 important miRNAs analyzed, two of them remained consistent in their expressions (miR-17-3p 
and miR-147b) and one differed (miR-299-5p). The in-silico approach helped determine miRNAs 
that were prominent not just in one body fluid but other body fluids as well. This indicates that 
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some of these miRNAs can serve as potential biomarkers for prostate cancer and help alleviate this 
disease by utilizing these miRNAs as potential therapeutic targets.   
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Chapter 2: 
Elucidation and confirmation of miR17-3p binding sites within 
3’UTR of ErbB2 
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2.1 History of miR-17-3p and its target vimentin: 
As previously described, the Zehner laboratory works with a SV40T, immortalized human 
prostate cancer cell line progression model known as M12. This highly metastatic and tumorigenic 
cell line was developed from a parental cell line, P69, which is poorly tumorigenic and derived 
from normal prostatic tissue. Identifying potential miRNAs and their mRNA targets in the related 
M12 and P69 cell lines will aid in determining which miRNAs are required for the progression of 
prostate tissue from benign to tumor.  
Vimentin is the type of intermediate filament protein (IFP) found in normal mesenchymal 
cells, where it plays an important role in maintaining cellular integrity and provides resistance 
against stress. It has been shown that vimentin levels are increased in epithelial cancers such as 
prostate cancer, gastrointestinal tumors, breast cancer, malignant melanoma, lung cancer and other 
types of cancers [42, 43]. Vimentin is an important marker for the epithelial-mesenchymal-
transition (EMT), which is known to be associated with tumorigenesis for a variety of different 
cancers [35]. Additionally, vimentin affects cell motility by enhancing metastasis in highly 
tumorigenic cell lines. One study showed that vimentin was more likely to be expressed in highly 
metastatic and tumorigenic cell lines than in slightly tumorigenic or non-metastatic cell lines [36]. 
Similarly, previous work done in the Zehner laboratory showed that vimentin mRNA was highly 
expressed in the highly tumorigenic and metastatic M12 cell line, but expressed less in the poorly 
tumorigenic and non-metastatic P69 cell line [34]. In order to control the high level of vimentin in 
the M12 cell line, miR-17-3p was identified as one miRNA capable of binding to vimentin’s 
3’UTR. The parental P69 cell line contained miR-17-3p and expressed little vimentin whereas, the 
M12 cell line showed a loss of miR-17-3p, suggesting this miRNA might be a tumor suppressor. 
Restoration of miR-17-3p in the M12 cell line through stable transformation with a miR17-3p 
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expression plasmid, resulted in a 5-fold increase in miR-17-3p levels, which in turn led to a 
considerable decrease in vimentin protein expression. In fact, an almost perfect binding of miR-
17-3p to vimentin mRNA further confirmed that this mRNA was a strong target for miR-17-3p 
binding [32].  
2.2 Finding additional 3’UTR mRNA targets for miR-17-3p: 
In an attempt to find additional mRNA targets for miR-17-3p, three successive passages of 
M12, M12+miR-17-3p and M12’s parental cell line P69 were sent to Dr. Emanual Petricoin of 
George Mason University for proteomic analyses via Reverse Phase Protein Microarray (RPMA). 
The results revealed that the expression of c-Kit, ErbB3, and ErbB2 were the most significantly 
phosphorylated proteins whose expressions differed between the M12 and P69 cell lines [34].          
C-kit was confirmed to be a relevant target for miR 17-3p by western blots, as shown by Seashols, 
dissertation (2013) [34].  
2.3 Mir-17-3p a potential target for 3’UTR ErbB2: 
Together with c-KIT, RPMA proteomic analyses revealed that ErbB2 and ErbB3 protein levels 
were significantly up-regulated, a 1.7- and 2.0- fold increase respectively from the P69 to M12 
cell lines.  Interestingly, there was no significant change observed in ErbB2 levels from the M12 
to M12+miR17-3p cell line, but with a phospho-specific antibody to ErbB2, a 1.6-fold decrease 
was obtained.  It was felt these inconsistent results warranted further investigation to determine if 
ErbB3 and/or ErbB2 actually contain miR17-3p binding sites or is regulation being exerted 
indirectly through an unknown kinase which in turn regulates ErbB2 activity. Since luciferase 
constructs containing ErbB2's 3'UTR were readily available, we started with ErbB2 as it did 
exhibit a significant change in expression in at least one direction, i.e., p69 to M12 [40]. 
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2.4 Epidermal growth factor receptor (ErbB2): 
 The ErbB2 (also known as HER2, neu, and NGL) belongs to the epidermal growth factor 
receptor (EGFR) family [41]. Located on chromosome 17q12 from base pairs 39,688,139 to 
39,728,661 [40], this gene encodes a 185-kDa transmembrane glycoprotein with phospho- tyrosine 
activity. Overexpression of this gene has been known to enhance metastasis-related properties such 
as invasion, angiogenesis, and prolonged growth of cancerous cells, which ultimately leads to 
metastases. Overexpression of this gene also causes cancerous cells to gain resistance to various 
chemotherapies and radiation, resulting in a poor response to cancer treatment [41]. If miR-17-3p 
either by direct or indirect binding can reduce the activity of ErbB2 in cancerous cells, it might 
represent a relevant therapy for slowing growth, stopping metastasis and eventually enhancing the 
elimination of cancerous cells through apoptosis. 
2.5 Computational analyses of ErbB2 and miR-17-3p: 
The miR-17-3p sequence (5’ACUGCAGUGAAGGCACUUGUAG 3’) was obtained from 
miRBase [25] and the sequence of ErbB2’s 3’UTR was obtained from the study conducted by 
Scott et al [38]. The sequence of ErbB2’s 3’UTR and miR-17-3p was analyzed by RNA-hybrid 
[37], a structural hybridization prediction tool for measuring the minimum free energy (mfe, or 
ΔG) based on the alignment of miRNA to mRNA. Surprisingly, three potential miR-17-3p binding 
sites were observed in ErbB2’s 3’UTR of 576 nts in length. The first miR-17-3p site was located 
at position 44, with a second and third site located at positions 110, and 451 respectively. Table 2-
1 depicts the structural interaction of miR-17-3p to the 3’ UTR of ErbB2. Based on the proposed 
strong binding of miR-17-3p to ErbB2’s 3’UTR, as suggested by the favorable mfe, it is possible 
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that one or more of these sites represent favorable binding sites for miR-17-3p which warrants 
experimental validation. 
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A: Mir-17-3p site located on 
position 44 
 
MFE: -24.5 kcal/mol 
Position  44 
ErbB2 5'  A     GAAG    GACUU    U G 3' 
            GCAGG    GCCU     CUGC G     
            UGUUC    CGGA     GACG C     
miRNA  3' GA     A       AGU      U A 5' 
 
 
B: Mir-17-3p site located on 
position 110 
 
MFE: -15.3 kcal/mol 
Position  110 
ErbB2 5' C    CA     AGGAA      C   3' 
           CUGC   UGCC     C CUGU       
           GAUG   ACGG     G GACG       
miRNA  3'      UUC    AA    U    UCA 5' 
 
 
C: Mir-17-3p site located on 
position 451 
 
MFE: -24.4 kcal/mol 
Position  451 
ErbB2  5' G     G              UU   U 3' 
           UACA  AGUGCUUUU CUGU  AGU     
           AUGU  UCACGGAAG GACG  UCA     
miRNA  3' G               U           5' 
 
 
Table 2-1: The three potential miR-17-3p binding sites (at 5’-position 44, 110, and 451 all 
extending to 576) within the 3’UTR of ErbB2 from RNA-hybrid software. The value of ∆G 
indicates the strength of binding between a miRNA and its target mRNA. A low ∆G value indicates a 
stronger binding affinity. The miR-17-3p binding sites at position 44 and 451 exhibit the strongest 
binding affinities with a nearly identical ∆G value of -24 kcal/mol.   
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2.6 Elucidation of possible miR-17-3p binding sites between 44/576, 110/576, and 451/576 
within the 3’UTR of ErbB2:  
To determine which site(s) within the 3’UTR of ErbB2 was being repressed the most by miR-17-
3p binding, successive 5’-end deletions were prepared as seen in figure 2-1. The construct 44/576 
retains all three possible binding sites at positions 44, 110 and 451. Whereas, construct 110/576 
lacks site # 1 and finally construct 451/576 retains only site # 3.  
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Figure 2-1:  The 3’UTR of ErbB2 showing the three binding sites of miR-17-3p at positions 
44, 110, and 451 extending to the common 3’-end at nucleotide 576. The arrows are color 
coordinated with the boxes representing each site and depict how 5’-deletions of each position 
were prepared. The sequence of the 3’UTR from ErbB2 was from Scot et al [38], whereas the 
miR-17-3p sequences were obtained from miRBase [25].  MiR-17-3p binding sites on the 3’UTR 
of ErbB2 were deduced using RNA-hybrid software [37]. Each of the miR-17-3p sites were 
constructed by deleting sequences upstream of each position, but maintaining downstream 
sequences. Thus, construct 44/576 retained all three possible binding sites, whereas construct 
110/576 had deleted site # 1, and finally construct 451/576 retained only site # 3.  
 
 
 
 
 
 
 
37 
 
2.7 The Goals of this chapter are as follows: 
1. Determine which site(s) on the 3’UTR of ErbB2 repressed the most and contributed to the 
low level of ErbB2 in M12+miR-17-3p cell line. 
2. To study the third miR-17-3p site (451/576) on the 3’UTR of ErbB2. This is the only site 
whose effect can be monitored independently, and not be influenced by other two sites, 
since they are deleted.  
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2.8 Methods and Materials 
Maintenance of cells 
     M12 and M12+miRNA media preparation: 
In 500 ml of RPMI 1640 supplemented with L-glutamine (Caisson Labs, North Logan, 
UT), 5% fetal bovine serum (25ml), 250ul of 2000X ITS which consists of 5ug/ml Insulin, 5ug/ml 
Transferrin, and 5ug/ml Selenium from Collaborative Research, Bedford, MA and 500ul of 
Gentamycin [0.05 mg/mL] was added as a growth media for the M12 cell line. M12 cells that were 
stably transformed with the p-SIREN plasmid vector expressing miR-17-3p were maintained using 
reagents mentioned above and selected with an additional drug, 125ul of puromycin [100ng/ml] 
[32].   
Cell culture: 
 Cells were cultured in a 75cm2 flask and passaged when they reached 65-70% confluency. 
No cells were cultured above 27 passages. M12 cells remained adherent to the surface of the flask. 
To pass cells, 2-3mls of  pre-heated 0.025% Trypsin-EDTA (Gibco-Life Technologies, Carisbad, 
CA), were added to the cells and incubated at 37°C for 5-7 minutes. To inactivate trypsin, 8 mls 
of M12 media (for the M12 cell line) or M12+miRNA media (for M12+miR cell line containing 
maintenance level of puromycin) were mixed with the trypsin/cell solution and cells pelleted by 
centrifugation at 1500xg for 5 minutes. The cell pellet was either passaged, or plated based on 
experimental requirement. 
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PCR and Cloning of 3’ UTR construct: 
The 75nt long site# 3 at position 451 
(GAGCTCTTTGTACAGAGTGCTTTTCTGTTTAGTTTTTACTTTTTTTGTTTTGTTTTTTTAAAGA
TGAAATAAAGACCCAGGTCTAGA) was amplified via Polymerase chain reaction (PCR). The 
forward primer was ordered from Invitrogen, Grand Island, NY, USA, and PCR was 
programmed as follows: 1 cycle at 95°C for 2 min; 30 cycles at 95°C for 30 seconds, followed 
by 65°C for 30 seconds, 72°C for 1 minute; 1 cycle at 72°C for 10 minutes; stored at 6°C until 
removed from the machine. The PCR product was directionally cloned into the pmiR-Glo vector 
(Promega Corporation, Madison, WI) digested with Sacl (red) and Xbal (purple) restriction 
enzymes within the multiple cloning site (MCS) downstream of the luciferase gene using 
standard digestion and ligation procedures. Upon successful transformation into Escherichia coli, 
and sequence confirmation from Virginia Commonwealth University (VCU) Nucleic Acids 
Research Facilities (NARF) [58], the plasmid was purified via Qiagen midi-prep kit and used for 
transfections into the M12+miR-17-3p cell line.  
Transfection: 
 After culturing the cells, the pellet was suspended in 11ml of PBS from which 1mL was 
used for counting the cells in a Coulter Counter® Analyzer (Beckman Coulter, Inc., Brea, CA) or 
Vi-Cell™ XR Cell Viability Analyzer (Beckman Coulter, Inc.) using a trypan blue solution. The 
remaining 10mL of PBS was centrifuged at 1500xg for 5 mins and the pellet re-suspended in the 
appropriate volume of media to yield 25,000 cells/500ul aliquot of M12 or M12+miR-17-3p cells 
and plated in a 24-well plate. Each plate was left for incubation at 37°C for 24 hours. Transfections 
were performed in triplicate. The following day a master mixture was prepared containing per 
well, pmiR-Glo plasmid (500 ng of vector containing different fragments of ErbB2’s 3’UTR as 
 
 
 
40 
 
indicated, 2uL of TransIT®-LT Transfection Reagent (Mirus BIO LLC, Madison, WI, USA), and 
50uL of RPMI. The master mix was incubated at room temperature for a minimum of 30 mins. 
Meanwhile, the media from the previous day was replaced with 500uL of fresh media. The master 
mix was added to each well drop wise and the plate was incubated at 37°C for 24-48 hours. After 
incubation the cell media was aspirated and the attached cells washed with 500uL of PBS. Passive 
lysis buffer (1X) (Promega Corporation) was added to each well (100uL) and allowed to rock back 
and forth on a platform shaker for 15 min. The cells/buffer solution were scraped off the well and 
stored in eppendorf tubes at -20°C until the luciferase assay was conducted. 
                  Luciferase Assay: 
 The luciferase assay was conducted using the Dual-Luciferase Reporter Assay System 
(Promega Corporation). For this assay the renilla control substrate was prepared, by diluting the 
Stop & Glo substrate, 1:50 in Stop & Glo solution. One ml of Luciferase Assay Reagent II (LAR 
II) aliquots was prepared by suspending the luciferine powder in 10 ml luciferase substrate. Once 
prepared, Stop & Glo (renilla) and LAR II luciferase activities of the cell lysates were measured 
in the GloMax® 20/20 Luminometer (Promega Contribution) [34]. To an aliquot of thawed cell 
lysate (20ul), 30 ul of LAR II was added and firefly luciferase activity was measured at a 
wavelength of 560nm. After 3 seconds, 30ul of renilla substrate was added and renilla activity 
measured at a wavelength of 480nm. Reporter activity is presented as a ratio of firefly luciferase 
to renilla luciferase activity. Data was analyzed via the Microsoft® Excel software platform, using 
the average and standard deviation function with a statistical significance of p ≤ 0.05. 
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2.9 RESULTS 
 Three potential miR-17-3p binding sites were predicted within ErbB2’s 3’UTR of 576 nts 
as follows: site #1 at position 44, site #2 at position 110 and site # 3 at position 451. To determine 
which site(s) was essential in reducing the level of ErbB2, 5’-deletion constructs of these sites 
were prepared as described above. The activity of each construct was assessed in the M12+miR-
17-3p cell line since, this cell line expresses miR-17-3p.  
The result of transfection and luciferase assay of each construct, 44/576, 110/576, or 
451/576, inserted into the p-miR-Glo vector compared to the empty vector, revealed  that construct 
44/571 (including all three potential binding sties), decreased luciferase activity the most at 48% 
(0.52 fold decrease), as expected since it included all three possible binding sites. Construct 
110/576 (deleting site #1, but containing site # 2 and #3) decreased activity 39% (0.61 fold 
decrease) whereas construct 451/565 (containing only site # 3) exhibited a 15% (0.85 fold) 
decrease. Investigation of each deleted position indicates that removal of site # 1 at position 44 did 
not result in a large difference in luciferase activity, with only a 9% increase. However, an increase 
of 24% in luciferase activity was discovered when site #2 at position 110 was deleted (Figure 2-
2). This analyses indicates that site # 1 at position 44/576 was not an essential site within the 
3’UTR of ErbB2 for miR-17-3p binding, while site # 2 at position 110/576 and site # 3 at position 
451/576 were more essential.  
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Figure 2-2: Luciferase assays of miR-17-3p’s binding sites within ErbB2’s 3’UTR constructs 
of 44/576; 110/576; and 451/576 compared to the empty pMiR-Glo vector. Each construct was 
transfected into the M12+miR-17-3p cell line and firefly luciferase activity measured at 
wavelength of 560nm versus Stop & Glo (renilla) at a wavelength of 480nm Expression was 
normalized to the empty pMirGlo vector. Each construct was analyzed in triplicate (p ≤ 0.05).  
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2.10 Discussion 
Proteomics analyses showed that ErbB2 was significantly up-regulated in the highly 
metastatic M12 cell line while no significant change was observed in the M12+miR-17-3p cell 
line. Yet a 1.6X decrease was observed for pErbB2 protein levels in the M12+miR-17-3p 
compared to the M12. However, since a change in expression for ErbB2 was observed from P69 
to M12 cell line and dysregulation of miR-17-3p was observed in the M12 cell line, there was a 
possibility that miR-17-3p had a binding site within ErbB2’s 3’UTR. Here, three potential miR-
17-3p binding sites within ErbB2’s 3’UTR were analyzed which together were shown to contribute 
to a major reduction (48%) in luciferase activity. Surprisingly 5’-deletion mapping indicated that 
site # 2 might be the most effective in reducing luciferase activity as elimination of this region 
resulted in a 24% restoration of activity. Site #1 on its own only yielded a 9% increase whereas 
site #3 yielded 15%.  There is no doubt that together all three sites are the most efficient in 
recruiting miR-17-3p and in the cell would be the most responsive to miRNA regulation of ErbB2 
synthesis.  
These analyses revealed that site # 2 and somewhat site # 3 are probably the most effective 
binding sites with ErbB2’s 3’UTR for miR-17-3p binding. This conclusion did not confer with the 
results obtained from RNA-hybrid [37] for deducing the best binding sites for miR-17-3p on 
ErbB2’s 3’UTR based on mfe as a valid measurement of binding efficiency. RNA-hybrid [37] 
showed site # 1 and site # 3 to be the best binding sites, whereas, luciferase assay conducted in our 
highly metastatic prostate cancer M12+miR-17-3p cell line, revealed that site # 2 and site # 3 were 
the best binding sites within the 3’UTR of ErbB2. The variation among these two type of analyses 
could be due to a variety of reasons.  First, in deleting site # 2 a large section of  ErbB2’s 3’UTR 
was deleted (from bases 110 to 451) which might contain additional sequences (perhaps a partial 
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match to miR-17-3p) which independently presents an additional landing platform to assist miR-
17-3p binding to site #2. Secondly, there may be additional unknown miRNA binding sites within 
the 3’UTR of ErbB2, which in our cell line might be indirectly affecting miR-17-3p binding. Our 
miR screen analyses suggests that many miRNAs were differentially expressed in the various cell 
lines of our cancer progression model [40]. Therefore, there is a strong possibility that apart from 
miR-17-3p there are other potential miRNAs that are competing for binding to the 3’UTR of 
ErbB2.  In fact, there may be some undiscovered miRNAs with partial complementarity to site # 
1 which might be competing with miR-17-3p for binding; thus, contributing to the loss of 
repression to a site which due to a favorable mfe should be a strong binder for miR17-3p. 
To further understand the perceived strong binding by site #2, additional experimentation 
is required.  Since 5’-end deletion mapping generates a different 5’-end for each construct relevant 
to a fixed 3’-end, the results can sometimes be misleading. A better analysis would be to keep the 
same 3’-UTR sequence and mutate each potential site by site directed mutagenesis within that 
fixed 3’UTR segment. In this manner those specific bases complimentary to the seed region of 
miR-17-3p would be individually mutated for each site and then in various combinations, i.e., site 
# 1 + site # 2 or site # 2 + site # 3 and so on,  to determine exactly which site on its own is the most 
effective in binding miR-17-3p. 
In conclusion, these analyses confirmed that the 3’UTR of ErbB2 contains active sites for 
miR-17-3p binding.  This result confirms our proteomic analysis suggesting that ErbB2 is a direct 
target for miR-17-3p binding. Supporting the increase in ErbB2 protein levels in P69 to M12 cell 
line. The loss of miR-17-3p as a tumor suppressor in relevant prostate cancer cell lines and in 
tumor tissue by laser capture microdissection, suggests how the expression of ErbB2 is enhanced. 
ErbB2 is an important molecule in cancer. This gene belongs to the EGF family, a growth factor 
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receptor protein that is located on the cell surface enabling the activated receptor complex to relay 
signals in the cell. These signaling transduction pathways activate certain genes that promote cell 
growth [39]. Overexpression of ErbB2 has been linked to the metastatic potential of cancer cells 
and eventually these cancerous cells gain resistance to treatments such as radiation and 
chemotherapy. The network model analyses, previously conducted in our laboratory, revealed that 
ErbB2 proteins have highly connected nodes in prostate cancer, suggesting that these proteins are 
key regulators of development and progression of prostate cancer [40]. 
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Chapter 3: 
The significance of hsa-mir-299-5p, and possibly hsa-mir-299-3p, 
contributing to prostate cancer progression 
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3.1 Introduction and previous work: 
 Hsa-miR-299-5p and hsa-miR-299-3p are located on chromosome 14 (14q 32.31) from 
101490131 base pairs to 101490193 base pairs [44]. Both these miRNAs differed in expression 
in the human panel-miR analyses and single-miR analyses. Hsa-miR-299-5p was found to be a 
tumor suppressor exhibiting a 0.02-fold reduction in the panel analyses whereas a value for the 
single-miR analyses, at that time, was not obtained. An overexpression of 11.4-fold, was 
observed for hsa-miR-299-3p in the panel analyses, whereas a conflicting 0.035-fold loss of 
expression was observed in the single-miR analyses (Figure 3-i) [34]. Due to vast differences 
observed between panel analyses and single miR analyses, it felt further investigation on these 
miRNAs was important. 
 
 
 
 
 
Figure 3-i: Differential expressions observed between miR-299-3p and -5p for panel and 
single-miR analyses. In these analyses data was normalized against the global mean for panel and 
against RNU48 for single-miR analyses. M12 expression level was measured relative to the 
expression level of its parental P69 cell line for single miR analysis. MiR-299-3p was 
overexpressed in the panel analyses; however, highly reduced expression was observed for the 
single-miR analyses. Mir-299-5p appeared to be down-regulated in panel analyses, whereas no 
expression value was measured for single-miR analysis. 
     [Figure adapted from Seashols, dissertation (2013) [34]] 
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RNA was extracted via laser capture microdissection (LCM) from 5 patient biopsies, which were 
obtained by radical prostatectomies at different stages of prostate cancer. MiR Locked Nucleic 
Acid (LNA) RT-qPCR analyses of these patient samples showed that despite vast variability 
among patient samples some miRNAs remained consistent in their nature, while others varied. As 
mentioned in chapter 1, miR-9 and miR-147b, in particular, remained strongly consistent as 
oncomiRs in the model cell lines as well as in patient tumor samples. MiR-299-3p and miR-199-
3p, remained consistently low as tumor suppressors in model cell lines as well as patient tumor 
samples [Figure 3ii-B and C] [34]. However, MiR-299-5p is an unusual (or maybe irregular) 
miRNA as a number of fluctuations in its expression were observed, first during single-miR 
analyses and then during patient samples. Two individual experiments were performed on patient 
samples to measure the expression level of this miRNA. MiR-299-5p was found to be up-regulated 
in the first experiment consisting of three patient samples where miR-299 was detected (Figure 
3ii-A). However, in the other subsequent experiments miR-299-5p was down-regulated (Figure 3-
ii, B and C).  In the literature miR-299-5p has been reported to be down regulated in progressing 
from normal to localized tumor to metastatic cases of prostate cancer [44]. The great variation in the 
expression of miR-299-5p versus the consistent expression of                                                                                          
miR-299-3p both deriving from the same miR-299 precursor, demands further study. 
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Figure 3-ii: The expression levels of miR-299-3p and -5p observed for prostate cancer patients in 
benign and tumor samples. Two individual experiments were performed on patient samples. A-B: First 
experiment conducted on patient samples. The expression levels relative to benign revealed that miR-299-
5p was up-regulated in two patient samples, classifying it as an oncomiR. MiR-299-3p was down-regulated 
in two patient samples, classifying it as a tumor suppressor. C-D: Second repeats conducted on patient 
samples. The expression levels relative to benign, revealed that while miR-299-3p was consistently down-
regulated, so was miR-299-5p, now classifying it as a tumor suppressor. Another discrepancy seen here is 
for patient 10-036, in part A, miR-299-3p is seen as an oncomiR and in part C, miR-299-5p is seen as a 
tumor suppressor. Whereas, for patient 09-225, in part A, miR-299-5p is not detected, and in part D, miR-
299-5p is seen as a tumor suppressor.   
[Figure 3-ii-A-B were adapted from Seashols, dissertation [34], figure 3-ii C-D were adapted from former 
laboratory student J.H.] 
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3.2 Hsa-miR-299-5p 
Over the last years miR-299-5p has gained importance in a variety of developmental and 
disease related studies. For example, one report found a link between miR-299-5p and pregnancy. 
Together with other miRNAs, miR-299-5p was detected at a high level before delivery with a drop 
to null after delivery [45]. Another report studied the regulation and role of up-regulated miRNAs 
localized to the chromosome 14q32 miRNA cluster, in interstitial lung disease and idiopathic 
pulmonary fibrosis (IPF), found that both miR-299-5p and miR-299-3p among other miRNAs 
were significantly up-regulated. [46].   
For prostate, targets regulated by miR-299 are not well known; thus, it is important to find 
relevant targets which correlate with prostate cancer, and determine if changes in miR-299-5p or 
-3p expression affect the presence of proposed target mRNA/protein levels.  
3.3 Osteopontin (OPN):  
The literature suggests that osteopontin (OPN) is targeted by miR-299-5p. OPN is known 
as secreted phosphoprotein 1 (SPP1), a secreted glycosylated phosphoprotein that consists of 2% 
non-collageneous proteins in bone. It is present in all body fluids and an increase in its expression 
is known to correlate with tumor invasion and metastasis in prostate, colon, lung, breast and other 
cancers [47]. In a study that was performed to determine if OPN evokes a humoral immune 
response in PCa patients and if anti OPN antibodies can be used to differentiate PCa patients from 
healthy individuals, it was found that OPN was over expressed in prostate cancer and contributed 
to the progression of the disease. Healthy donors, biopsy proven PCa patients, and patients with 
benign prostate hyperplasia (BPH) were tested using recombinant human OPN. The frequency of 
anti-OPN antibodies found in the PCa samples was higher than in BPH and healthy individuals. 
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Based on these results the study proposed that anti-OPN antibodies may be used as an early serum 
marker for PCa [48]. Similarly, the importance of OPN was determined in the MCF10DCIS cell 
line for breast cancer. MCF10 is a model cell line consisting of normal immortalized breast 
epithelial cells [49]. The MCF10DCIS cell line was established from a xenograft lesion originating 
from premalignant MCF10AT cells injected into combined immune-deficient mice. This study 
found that when MCF10DCIS cells were grown as spheroids the oncogenic protein OPN was 
secreted in high levels thereby contributing to tumorigenicity. It was shown that OPN expression 
was down-regulated in MCF10DCIS spheroids due to being targeted by hsa-miR-299-5p. It is 
possible that the 3’-UTR of OPN may contain a binding site that is recognized by hsa-miR-299-
5p [50]. 
3.4 Binding of miR-299-5p to the 3’UTR of OPN: 
 There is not much literature that provides evidence of the 3’UTR of OPN being a 
proven target for hsa-miR-299-5p. However, one study conducted experiments on the multicellular 
spheroid-forming sub-population (SFC) of the following  human breast cancer cells,  MCF-7, 
MC10AT, and MCF10DCIS compared to COS-7, to determine if  the 3’UTR of OPN contains a 
binding site for hsa-miR-299-5p [50]. Among various experiments conducted, one experiment 
determined that OPN indeed evoked tumorigenicity in breast cancer cells. The results showed that 
upon abrogation of OPN expression by adding a neutralizing anti-OPN antibody, the proliferation 
rate of the MCF7-SFC and MCF10DCIS-SFC cells was reduced to 40% and 60%, respectively 
[50]. In order to confirm whether the 3’UTR of OPN was bound by hsa-miR-299-5p, the 
MCF10AT cells and MCF10DCIS cells were transfected with an anti-miRNA-inhibitor specific 
for hsa-miR-299-5p. Initially, upon transfection with 40 nM of anti-mRNA inhibitor, the levels of 
hsa-miR-299-5p remained unaltered; however post 48 hours of treatment, the levels of OPN up-
 
 
 
52 
 
regulated and increased even further in correlation with increasing the amount of inhibitor to 60nM 
and ultimately 100nM [50]. This result confirms that with increasing concentrations of anti-
miRNA inhibitor, the ability of hsa-miR-299-5p to bind to OPN's 3’UTR decreased resulting in a 
concomitant increase in OPN protein levels. Lastly, the ability of hsa-miR-299-5p to bind to the 
3’UTR of OPN was tested in two cell systems, COS-7 and MCF10A. The 3'UTR of OPN mRNA 
was cloned downstream of a luciferase reporter in the pmiR-Report vector to generate pmiR-
Report-OPN and co-transfected with hsa-miR-299-5p into COS-7 or MCF10A cells resulting in a 
42% and 30% reduction in luciferase activity, respectively [51]. This experiment confirmed that 
the 3’UTR of OPN contains a binding site for hsa-miR-299-5p. 
3.5 Hsa-miR-299-3p 
Studies have shown that the androgen receptor (AR) is targeted by hsa-miR-299-3p [52]. 
Initially, androgen is important for the growth of prostate cancer and one way to control PCa is to 
inhibit AR; however, overtime prostate cancer becomes AR independent and continues to thrive. 
AR is expressed in all stages of prostate cancer hence miRNAs could be used to control the 
development of PCa. Ostling et al. found that the AR has an unusually long 3’UTR (>6Kb) which 
is regulated by 13 miRNAs. Among those miRNAs, transfection of a miR-299-3p mimic resulted 
in a decrease of AR expression as measured with the relevant luciferase:AR-3'-UTR fusion 
construct [52]. Since AR is critical for progression of prostate cancer, an initial treatment for 
prostate cancer is removal of AR. In normal prostate, AR promotes survival and differentiation, 
but during prostate cancer development it becomes an inducer of uncontrolled cell growth. With 
hsa-miR-299-3p being a potential tumor suppressor, its restored expression in prostate cancer and 
in relevant cell lines in vitro could possibly result in decrease expression of AR, therefore 
inhibiting uncontrolled prostate cancer cell growth. 
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3.6 Experimental Aims 
To the best of our knowledge, no study has published the effect of hsa-miR-299-5p binding to 
the 3’-UTR of OPN in prostate cancer. Furthermore, no study has engineered a prostate cancer cell 
line to stably overexpress miR-299-5p or miR-299-3p and monitored the consequences to cell 
behavior. Previous studies have only co-transfected the miRNA with its known luciferase reporter 
construct fused to the target 3’UTR (luc:3'UTR) to validate a decrease in luciferase activity 
dependent on increased miRNA content. Henceforth, the goals of this research were to: 
1. Restore the expression of miR-299 in the M12 cell line, using the precursor hsa-miR-299 
expression plasmid from GeneCopoeia [53] to create a stable transformant to be named 
M12+miR-299.  
2. Conduct q-RT-PCR on the M12 cell line and M12+miR-299 cell line to determine which 
mature hsa-miR-299 (-5p or -3p or both) was being produced in our prostate cancer cell 
line. 
3. Confirm the functional consequences of altered miR-299 expression on target mRNA 
expressions using the pmiR-Glo luciferase: fusion  plasmid construct (Luc:OPN3’UTR) 
4. Determine if repression of luciferase activity is observed dependent on the inclusion of 
OPN’s 3’UTR then ultimately construct mutants of relevant nucleotides within the OPN’s 
3’UTR target and re-assay.  
5. Conduct migration, invasion and proliferation assays on M12 vs. M12+miR-299 to 
determine the effect of altered miR-299 expression on migratory abilities and cell behavior. 
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3.7 Methods and Materials: 
M12 and M12+miRNA media preparation: 
In 500 ml of RPMI 1640 supplemented with L-glutamine (Caisson Labs, North Logan, 
UT), 5% fetal bovine serum (25ml), 250ul of 2000X ITS which consists of 5ug/ml Insulin, 5ug/ml 
Transferrin, and 5ug/ml Selenium from Collaborative Research, Bedford, MA and 500ul of 
Gentamycin [0.05 mg/mL] was added as a growth media for the M12 cell line. M12 cells that were 
stably transformed with the p-miRGlo plasmid vector expressing miR-299-5p were maintained 
using reagents mentioned above and selected with an additional drug, 125ul of puromycin 
[100ng/ml] [32].  
Preparing to insert the miR-299 precursor in the M12 cell line: 
The hsa-miR-299 precursor gene, as a stem-loop expression plasmid was obtained from 
(GeneCopoeia™,Rockville,MD).     
(5’AAGAAAUGGUUUACCGUCCCACAUACAUUUUGAAUAUGUAUGUGGGAUGGUAAACCGCUUCUU3’) as 
a bacterial broth.  Escherichia coli was transformed with 25ul of the bacterial broth, plated on LB 
agar plates containing the antibiotic ampicillin, colonies picked, and plasmid purified by standard 
mini-prep purification methods. After confirming the sequence of the precursor through Virginia 
Commonwealth University, Nucleic Acid Research Foundation (VCU-NARF) [58] a larger scale, 
Midiprep (Qiagen) was performed to extract DNA suitable for transfecting the miR-299 plasmid 
into the M12 prostate cancer cell line.  
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Stable Transfection 
In 25 cm2 flask 1.5 x 105 M12 cells were plated in the appropriate serum containing media for 24 
hours. The following day a mixture of  plasmid DNA (6.5 µg) containing the miR-299 gene insert, 
19.5 µl of TransIT®-LT Transfection Reagent (Mirus BIO LLC, Madison, WI, USA) and 650 µl 
of serum/additive free RPMI media was mixed together and left for incubation at room temperature 
for 30 minutes. The solution was then added drop-wise to each flask, gently rocked back and forth, 
and placed in the 37°C incubator for 42 hours. The old serum and additives free RPMI media was 
aspirated off and stable transformants selected using cell culture media containing 200 ng/mL of 
Puromycin for four weeks. After four weeks, the cells, now known as M12+miR-299, were 
maintained with cell culture media containing 100ng/mL puromycin (maintenance level).  
Maintenance of cells 
Cell culture: 
Cells were cultured in a 75cm2 flask and passaged when they reached 65-70% confluency. No cells 
were cultured above 27 passages. M12 cells remained adherent to the surface of the flask. To pass 
cells, 2-3mls of  pre-heated 0.025% Trypsin-EDTA (Gibco-Life Technologies, Carisbad, CA), 
were added to the cells and incubated at 37°C for 5-7 minutes. To inactivate trypsin, 8 mls of M12 
media (for the M12 cell line) or M12+miRNA media (for M12+miR cell line containing 
maintenance level of puromycin) were mixed with the trypsin/cell solution and cells pelleted by 
centrifugation at 1500xg for 5 minutes. The cell pellet was either passaged, or plated based on 
experimental requirement. Refer below to “cell pellet preparation” in order to extract RNA.  
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Cell pellet preparation: 
 
Cell pellets (either M12 or M12+miR-299) were washed with 10 mL of PBS and re-centrifuged at 
8000xg for 5 minutes and supernatant removed and the cell pellet washed one more time with PBS  
as above. The cell pellets were flash frozen in liquid nitrogen and stored at 80°C for at least 24 
hours.  
RNA extraction from cell pellets: 
 
RNA was extracted using the miRVana™ RNA isolation kit and recommended protocol (Ambion-
Life Technologies, Carlsbad, CA). RNA was eluted in 50 µl of Elution Buffer and stored in -80°C. 
RNA concentration was measured using the NanoDrop ND-2000 Spectrophotometer (Thermo-
Fisher Scientific, Inc., Waltham, MA) [34].  
 
cDNA synthesis: 
 
For cDNA synthesis and mRNA quantification the QScrip™ cDNA synthesis kit (Quanta 
Biosciences, Gaithersburg, MD) was used. cDNA was prepared in thin-walled PCR tubes using 1-
7µl of RNA [1 µg down to 10 pg], 2µl of Poly(A) Tailing Buffer (5X), and 1µl of Poly(A) 
Polymerase. The mixtures were vortexed and centrifuged for 10sec to collect the contents. The 
tubes were placed in the thermal cycler programmed as follows: 1 cycle at 25°C, 1 min; 1 cycle at 
37°C, 40 min; 1 cycle at 70°C, 5min, followed by 6°C, 5-10min; During the hold period 10µl of 
Poly(A) Tailing reaction, 9µl of microRNA cDNA Reaction Mix and 1µl of qScipt Reverse 
Transcriptase was added to each tube. The tubes were placed back in the thermal cycler program 
resuming from 6oC and moving to 1 cycle at 42oC for 20 minutes and 85oC for 5 min. The tubes 
were stored at -80°C for further analyses. 
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QPCR: 
In a 96-well-plate miRNA content of cDNA from M12 and M12+miR-299 was analyzed. Each 
experiment was performed in triplicate. Five master mixes were prepared containing: Quanta 
Biosciences, Gaithersburg, MD, 10uM (0.25uL) - 299-3p primer, 299-5p primer, RNU-48, miR-
375 and miR-141, 6.25 uL SyberGreen, 2uL cDNA, and 4uL H2O. The QPCR instrument was 
programmed as Step 1: 1 cycle at 95°C for 2-3 minutes; step 2: 40 cycles at 95°C for 15seconds, 
60°C for 15 seconds, and 70°C for 30 seconds; step 3, 1 cycle at 95°C for 15 seconds, 60°C for 30 
seconds, and 95°C for 15seconds.  
   
   DNA Synthesis and cloning 
 
For the miR-299 target, osteopontin (OPN), two strands from the 3’UTR of OPN were synthesized 
as follows (Invitrogen, Grand Island, NY, USA).  
The 3’UTR OPN was found in the National Center for Biotechnology Information (NCBI) 
accession number: NM_001040058.1.  
The 1st strand OPN 9 (insert = 56nt) and 2nd strand OPN 13 (insert = 55nt) being  
1) 5’CGCGGCCGCCTTTACAACAAATACCCAGATGCTGTGGCCACATGGCTAAACCCTGACCCATCTCAGT3’ 
2) 5’ CAGTTTGTGGCTTCATGGAAACTCCCTGTAAACTAAAAGCTTCAGGGTTATGTCTAGCGGCCGCGT 3’ 
The red, blue and green are SACI, NOTI and ACCI restriction enzymes, respectively used for 
directional cloning digested into the pMir-Glo vector. Each oligonucleotide was re-suspended at 
100 uM. For annealing 9 ul of the forward and reverse strands was mixed with 2ul of 10X 
annealing buffer and heated at 95°C for 20 minutes. The mixture was allowed to cool at room 
temperature for 120 minutes, and based on experimental requirements was either stored at -20C or 
immediately used for ligation. OPN inserts were ligated into the p-Mir-Glo vector cut with SACI 
and ACCI restriction enzymes. The ligates were allowed to sit at room temperature for minimum 
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of 30 minutes and based on further experiments, was either used for transformation or stored at      
-20C. The standard cloning procedure was carried out and 5ul of the ligated products was 
transformed into DH5α Escherichia coli cells and 150ul or 250ul of the transformants were plated 
on agar plates and selected with the drug ampicillin. The standard miniprep following the 
manufacturer’s protocol (Qiagen) was carried out and DNA was sent to VCU-NARF [58] for 
confirmatory sequencing. Upon confirmation, midiprep DNA (Qiagen) based on the 
manufacturer’s protocol was performed to extract a plasmid suitable for transfection. For 
transfections only midiprep plasmid products were used due to the high purity and concentration 
of DNA obtained.  
   
Transfection of 3’UTR of OPN into M12 and M12+miR-299 cell lines 
 
After culturing the cells, the pellet was suspended in 11ml of PBS from which 1mL was used for 
counting the cells in Coulter Counter® Analyzer (Beckman Coulter, inc, Brea, CA) or Vi-Cell™ 
XR Cell Viability Analyzer (Beckman Coulter, Inc) [34] using trypan blue solution. The remaining 
10mL of PBS was centrifuged at 1500xg for 5 mins and pellets re-suspended in the appropriate 
volume of media to yield 25,000 cells/500ul. Aliquots of M12 and M12+miR-299 cells were plated 
in a 24 well plate and left for incubation at 37oC for 24 hours. Each sample was performed in 
triplicate. The following day a master mixture was prepared, containing per well pmiR-Glo 
plasmid (500 ng of vector containing the 3’UTR of OPN), 2uL of TransIT®-LT Transfection 
Reagent (Mirus BIO LLC, Madison, WI, USA), and 50uL of RPMI. The master mix was incubated 
at room temperature for a minimum of 30 min. Meanwhile, the media from the previous day was 
replaced with fresh media. The master mix was added to each well drop wise and the plate 
incubated at 37oC for 24-48 hours. After incubation, the cell media was aspirated and the attached 
cells washed with 500ul of PBS. 100ul of 1X Passive Lysis Buffer (Promega Corporation) was 
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added to each well and allowed to rock back and forth on a platform shaker for 15 min. The 
cells/buffer solution was scraped off the well and stored in eppendorf tubes at -20oC until needed 
to conduct luciferase assay.  
     Luciferase Assay: 
 
 The luciferase assay was conducted using the Dual-Luciferase Reporter Assay System 
(Promega Corporation). For this assay the renilla control substrate was prepared, by diluting the 
Stop & Glo substrate, 1:50 in Stop & Glo solution. One ml of Luciferase Assay Reagent II (LAR 
II) aliquots was prepared by suspending the luciferine powder in 10 ml luciferase substrate. Once 
prepared, Stop & Glo (renilla) and LAR II luciferase activities of the cell lysates were measured 
in the GloMax® 20/20 Luminometer (Promega Contribution) [34]. To an aliquot of thawed cell 
lysate (20ul), 30ul of LAR II was added and firefly luciferase activity was measured at a 
wavelength of 560nm. After 3 seconds, 30ul of renilla substrate was added and renilla activity 
measured at a wavelength of 480nm. Reporter activity is presented as a ratio of firefly luciferase 
to renilla luciferase activity. Data was analyzed via the Microsoft® Excel software platform, using 
the average and standard deviation function with a statistical significance of p ≤ 0.05. 
 Preparing the mutants of 3’UTR of OPN: 
For this analysis, it was felt that the length of the original OPN 3'UTR , needed to be shortened to 
minimize any possible shift in miR-299-5p binding to downstream sites containing a partial match. 
Thus, two new sets of original 3’UTR of OPN 9 and OPN 13 created were: 
1) (OPN 9 insert = 25nt) 5’CGCGGCCGCTGCTGTGGCCACATGGCTAAACCCTGT 3’ 
2) (OPN 13 insert = 26nt) 5’CAGTTTGTGGCTTCATGGAAACTCCCTGCGGCCGCGT 3’ 
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The mutants (underlined) created for 1 and 2 are as follows: 
1) OPN 9: 5’ CGCGGCCGCTGCTTTCACAACATTGCATTTTTCTGT 3’ 
2) OPN 13: 5’CAGTTAGAGTCTTCATTTTATTTCCCTGCGGCCGCGT 3’ 
As described above, the same methods for DNA synthesis, cloning, transfections, and luciferase assay were 
also performed.  
 Migration and Invasion Assay: 
Migration assay was carried out with M12 and M12+miR-299 cell lines. After culturing, cell pellets were 
suspended in 10ml of PBS from which 1mL was used for counting the cells in Coulter Counter® 
Analyzer (Beckman Coulter, inc, Brea, CA) or Vi-Cell™ XR Cell Viability Analyzer (Beckman 
Coulter, Inc) using trypan blue solution. Cells were collected by centrifuged at 1500xg for 5 
minutes as described above and re-suspended in RPMI media (no additives added) media in an 
appropriate volume. For the migration assay 50,000 cells per 200 uL were added to a ThinCert™ 
TC membrane support insert (Greiner Bio-one BVBA/SPRL, Belgium) and placed in a well in 24-
well plate. For the invasion assay before adding the cells, the ThinCert™ membrane support insert 
was layered with 30ul of a 10% solution of Cultrex® Basement Membrane Extract (Growth Factor 
Reduced), (R&D Systems®, Minneapolis, MN) mixed in RPMI 1640 medium and left to incubate 
at 37oC for 1 hour. After 1 hour 125,000 cells per 500ul were added to the membrane support 
insert. For both assays, as a chemoattractant- 1mL of, above mentioned, M12-media containing 
10ng/mL EFG was pipetted into the lower chamber of the well and the plate incubated at 37oC for 
20-24 hours. Media from both the membrane and lower chamber was aspirated off and cells fixed 
by adding 300uL of 0.025% glutaraldehyde in PBS to the membrane and the lower chamber for 
20 minutes. The glutaraldehyde was aspirated off and replaced with 0.1% Crystal Violet in 10% 
EtOH and PBS for a minimum of 30 minutes. The membranes were excised and mounted on a 
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microscope slide using Permount® (Fisher Scientific, Waltham, MA). Cells were counted on 5 
random fields for each replicate, averaged and expressed as relative to the control (M12 cell line). 
 Proliferation Assay 
After culturing the cells, the pellet was suspended in 10ml of PBS from which 1mL was used for 
counting the cells in Coulter Counter® Analyzer (Beckman Coulter, inc, Brea, CA) or Vi-Cell™ 
XR Cell Viability Analyzer (Beckman Coulter, Inc) using trypan blue solution. The rest 9mL of 
PBS was centrifuged at 1500xg for 5 minutes and suspended pellets in raw RPMI (no additives 
added) media and appropriate volume. Cells were harvested, pelleted and counted as described 
previously and re-suspended for this assay as 10,000 cells/100 uL for plating in a 96 well plate.  
Media plus or minus puromycin, but without cells was added to several additional wells to act as 
a negative control for background fluorescence or  M12 or M12+miR-299 cells, were plated in 9 
wells and incubated at 37oC for 24, 48, and 72 hours. At each time interval the media was aspirated 
and replaced with 100uL of fresh cell culture media. 10uL of 12mM MTT stock solution was 
added to each well, including the negative controls. The unit was incubated at 37oC for 4 hours. 
The MTT stock was prepared by adding 1mL of PBS to a vial containing 5mg of MTT. The 
mixture was voretexed or sonicated until dissolved. The resulting MTT solution can be stored for 
four weeks at 4oC, protected from light. After 4 hours, 85uL of the media was removed from each 
well and 50uL of DMSO was added and mixed thoroughly. The unit was incubated at 37oC for 10 
minutes, and the absorbance read at 540 nm.  
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3.8 RESULTS: 
The RT-qPCR results for M12 and M12+miR-299 (Figure 3-1) showed that miR-299-5p 
expression increased 18-fold in the M12+miR-299 stable transformants. There was no significant 
increase in miR-299-3p expression in the M12+miR-299 cells compared to its parental M12 cell 
line. From this result it can be concluded that the M12+miR-299 stable transformant is exhibiting 
an altered expression of only miR-299-5p. Also, the expression of other miRs such as miR-375 or 
miR-141, remained un-altered and exhibited no change in either the M12 or M12+miR-299 cell 
lines. This confirmed that inadvertently, the expression of other representative miRNAs was NOT 
being altered by the stable over expression of miR-299-5p.  
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Figure 3-1: The expression levels of miR-299-3p, miR-299-5p, miR-375, and miR-141 in the 
M12 and M12+miR-299 cell lines. RT-qPCR data was normalized to RNU48. The analyses 
confirmed that stable transformation of the M12 cell line with a miR-299 mini gene (M12+miR-
299-5p) resulted in enhanced expression of only miR-299-5p with no increase in expression of 
miR-299-3p or no effect on the expression of other unrelated miRNAs. Each sample was analyzed 
in triplicate (p ≤ 0.05). 
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A search of the literature revealed a binding site for miR-299-5p at position 1269-1290 within the 
3'UTR of OPN [51]. However, to determine if a better or additional binding sites is present, the 
3’UTR OPN was analyzed in RNA-hybrid [37] software. Table 3-1, shows two sequences within 
OPN's 3’UTR with the best possible matches for miR-299-5p. Among these two, one match 
(3’UTR OPN 13) coincided to that cited in the literature [51]. The mfe value, for 3’UTR OPN 9 
(position 280-301) was -20.9 kcal/mol whereas that for 3’UTR OPN 13 (position 1269-1290) was 
-19.7 kcal/mol suggesting that 3’UTR OPN 9 might be a better or at least an additional site for 
miR-299-5p binding. To determine which or if both sites are functional in vitro, each 3'UTR site 
was synthesized, cloned into the pmiR-Glo vector and the resulting luciferase activity analyzed in 
M12 or M12+miR-299-5p stably transformed cell lines. 
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Table 3-1: The miR-299 binding on the 3’UTR OPN 9 (56nt) and 3’UTR OPN 13 (55nt). On 
the left column are miR-299-5p (green sequence), OPN 9 (red sequence) with mfe of -20.9 
kcal/mol and OPN 13 (blue sequence) with mfe of -19.7 kcal/mol. The right column shows the 
binding of miR-299-5p (green sequence) to OPN 9 or OPN 13 (both red sequences). 
 
 
 
 
 
 
 
 
MFE: -20.9 kcal/mol (OPN 9) 
Position 281 
Target 5'     C     CCAC    C      C 3' 
               UGUGG    AUGG UAAACC     
               ACACC    UGCC AUUUGG     
MIRNA  3’ UACAU     C              U 5' 
 
 
MFE: -19.7 kcal/mol (OPN 13) 
Position 1269 
Target 5'  A  U     CUUC          C 3' 
            GU UGUGG    AUGG AAACU     
            CA ACACC    UGCC UUUGG     
miRNA  3' UA  U     C       A     U 5' 
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As anticipated the transient transfection of the luc:3’UTR-OPN9 and luc:3’UTR-OPN 13 plasmids 
in M12 and M12+miR-299 cell lines exhibited repression for both luc:3’UTR OPNs (figures 3-
2A, 3-2B, respectively). The results showed that, in comparison to the empty pmiR- Glo vector in 
the M12 cell line, OPN 9 binding site repressed luciferase activity 24% whereas OPN 13 repressed 
only 5%. Concurrently, the M12+miR-299 cell line compared to the empty pmiR-Glo yielded OPN 
9 and OPN 13 repression of 31%. The latter result was slightly better (1%) than what was found 
in the literature for similar transfections in the MCF10AT cell line (30%). Additionally, the 
repression rates of OPNs measured in M12 vs. M12+miR-299 showed that OPN 9 repressed 7% 
and OPN 13 repressed 26% more in the M12+miR-299 cell line. Thus, at this point it appeared 
that OPN 13 containing the miR-299-5p binding site with the slightly better mfe binding 
credentials exhibited greater inhibition in the M12 cell line.  However, in M12 cells engineered to 
overexpress miR-299-5p (M12+miR-299-5p) both OPN sites were comparable in capturing miR-
299-5p binding. 
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Figure 3-2A: The repression rates of 3’UTR OPN 9 and 3’UTR OPN 13 observed in the 
M12 cell line. A total of 2.5x104 M12 cells per 500uL were plated in a 24-well plate. The firefly 
luciferase reporter construct containing the 3’UTR OPN 9 or 3’UTR OPN 13 binding seed 
region (Table 3-1) along with a renilla luciferase plasmid were transfected into the M12 cell line. 
Reporter activity is presented as the ratio of firefly luciferase normalized to renilla luciferase 
activity. The expression value for each luciferase:3’UTR construct are reported relative to the 
empty p-miR-Glo vector (p ≤ 0.05) with each sample being analyzed in triplicate. 
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Figure 3-2B: The repression rates of 3’UTR OPN 9 and 3’UTR OPN 13 observed in the 
M12+miR-299-5p cell line. A total of 2.5x104 M12+miR-299-5p cells per 500uL were plated in 
a 24-well plate. The firefly luciferase reporter construct containing the 3’UTR OPN 9 or 3’UTR 
OPN 13 binding seed region (Table 3-1) along with a renilla luciferase plasmid were transfected 
into the M12+miR-299-5p cell line. Reporter activity is presented as the ratio of firefly luciferase 
normalized to renilla luciferase activity. The expression values for each luciferase:3’UTR 
construct are  reported relative to the empty p-miR-Glo (p ≤ 0.05) with  each sample being  
analyzed in triplicate.  
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To confirm that miR-299-5p was truly inhibiting the 3’UTR of OPN, mutants of 3’UTR OPN 9 
and 3’UTR OPN 13 were prepared to be transfected into the M12+miR-299 cell line and luciferase 
assays were conducted. As seen in figure 3-3 the original sequence of the 3’UTR OPN 9 (56nt) 
and 3’UTR OPN 13 (55nt) were shortened to produce a 25nt and 26nt length 3’UTR OPN 9 and 
OPN 13, respectively. The new sets of original sequences were further mutated (Figure 3-3). Table 
3-2 shows the comparison of mfe between the new sets of original 3’UTR OPN 9 and OPN 13 and 
their mutants. Figure 3-4 shows that the expression of the mutated 3’UTR' of OPN 9 and 13 in the 
M12+miR-299-5p had significantly increased 25% and 26% respectively compared to the new set 
of originals. 
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Figure 3-3A-C: The breakdown of old sets of original sequences of 3’UTR OPN 9 and OPN 
13 into new sets of original sequences and their mutants. The sequences of the original 3’UTR 
of OPN 9, OPN 13 and miR-299-5p were submitted to RNA-hybrid [37] program. In order to find 
the lowest mfe to create mutants, OPN 3'UTR, were shortened to minimize any possible shift in 
miR-299-5p binding to downstream sites containing a partial match. 3A represents old sets of 
original 3’UTR OPNs (56nts and 55nts) that were shortened to create 3’UTR OPNs (25nts and 
26nts) in 3B. The mfe of both old and new sets of originals were the same, and for both mutants 
OPN9 and OPN 13 were -5.2 kcal/mol and -11.1 kcal/mol respectively (Table 3-2).    
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Table 3-2: Comparison of mfe between the new shortened sets of 3’UTR OPN 9 (25nt) and 
3’UTR OPN 13 (26nt) and their mutants. Non-mutated and mutated- OPN 9 sequence is in red, 
OPN 13 is in blue and miR-299-5p is in green. The original 3’UTR mfe’s (Table 3-1) are identical 
to the new sets of shortened sites. As expected the mfe for the mutated sites is considerably reduced 
for the 3’UTR OPN 9 mutant as -5.2 kcal/mol and 3’UTR OPN 13 as -11.1 kcal/mol.   
 
 
3’UTR OPN 9 Original 
MFE: -20.9 kcal/mol (OPN 9) 
 
Position 281 
Target 5'     C     CCAC    C      C 3' 
               UGUGG    AUGG UAAACC     
               ACACC    UGCC AUUUGG     
MIRNA  3’ UACAU     C              U 5' 
 
3’UTR OPN 9 Mutant 
MFE: -5.2 kcal/mol 
 
Position  281 
Target 5'                  U   U 3' 
                            GCU     
                            UGG     
MIRNA  3' UACAUACACCCUGCCAUU   U 5' 
 
3’UTR OPN 13 Original 
MFE: -19.7 kcal/mol (OPN 13) 
 
Position 1269 
Target 5'  A  U     CUUC          C 3' 
            GU UGUGG    AUGG AAACU     
            CA ACACC    UGCC UUUGG     
miRNA  3' UA  U     C       A     U 5' 
 
3’UTR OPN 13 Mutant 
MFE: -11.1 kcal/mol 
Position  1269 
Target 5'     C     C            3' 
               UGUGG                
               ACACC                
MIRNA  3' UACAU     CUGCCAUUUGGU 5' 
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Figure 3-4: The increased expression rates for the mutated OPNs in the M12+miR-299 cell 
line. A total of 2.5x104 M12+miR-299-5p cells per 500uL were plated in a 24-well plate. New sets 
of original OPNs (brown and yellow bars) and mutated OPNs (purple and blue bars) from Table 
3-2 and Figure 3-3 were transfected into the M12+miR-299-5p cell line. The firefly luciferase 
reporter construct containing the 3’UTR OPN 9 or 3’UTR OPN 13 binding seed region (Table 3-
2) or mutated OPN 9 or OPN 13 were transfected together with the renilla luciferase normalization 
plasmid into the M12+miR-299-5p cell line. Reporter activity is presented as the ratio of firefly 
luciferase normalized to renilla luciferase activity. Expression values of each luciferase construct 
is reported relative to the original, non-mutated, OPNs (p ≤ 0.05) and each sample was analyzed 
in triplicate.  
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A proliferation assay was carried out between M12 and M12+miR-299 cell lines measuring growth 
at 24, 48 and 72 hours in duration. Figure 3-5 depicts that during 24 and 48 hours M12 and 
M12+miR-299 cells were growing at nearly the same rate with M12+miR-299 cells dividing 
slightly more often than the M12 cells. By 72 hours the growth of the M12+miR-299 cells started 
to decline slightly whereas the M12 cell line continued to grow gradually. It was expected that 
being a tumor suppressor the growth of M12+miR-299-5p will be slower than the M12 cells.  
In vitro experiments were conducted to determine if restoration of the potential tumor suppressor 
miR-299-5p displayed any functional consequences on cell behavior. Since, miR-299-5p 
overexpression did not affect growth rate, the effect on motility and invasion was measured next. 
Two sets of experiments were conducted: one with earlier passages of M12 and M12+miR-299 
cells, p15 and p18, respectively (Fig. 3-6 A, C) and the other with later passages, p25 and p27, 
(Fig. 3-6 B, D) respectively. For the migration assay, results varied slightly between an early or 
late passage, 1.8-fold versus 2.2-fold, respectively (Figure 3-6A compared to Figure 3-6B.). For 
invasion assay results varied widely between an early or late passage, 1.8-fold versus 0.85-fold, 
respectively (Figure 3-6C compared to 3-6D).  
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Figure 3-5: Cell proliferation conducted on M12 and M12+miR-299-5p at 24, 48, and 72 
hours shows that M12 and M12+miR-299-5p grow nearly at the same rate.  A total of 10,000 
cell per 100ul were plated in a 96-well plate. As a negative control media without cells were also 
plated. Each sample was analyzed 9 times, and incubated at 24, 48, and 72 hour intervals. At each 
point of time 12mM MTT stock solution was added to the wells and incubated at 37°C for 4 hours. 
After 4 hours, 85uL of the old solution was aspirated off, and 50ul of DMSO was added and mixed 
thoroughly. The unit was incubated at 37°C for 10 minutes, and the absorbance was measured at 
540 nm.  
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Figure 3-6A-D: A-B Migration assay for early and late cell culture passage of M12 and 
M12+miR-299-5p cell lines. C-D: Invasion assay for early and late cell culture passage of 
M12 and M12+miR-299-5p cell lines. M12 and M12+miR-299-5p cells were plated, for 
migration: 50,000 cells per 200ul; and for invasion: 125,000 cells per 500ul, on a ThinCert™ 
transwell membrane, with a layer of extracellular matrix added for invasion assay. After 24 hours 
the membrane containing the cells were mounted on a microscope slide and cells were counted on 
5 random fields. Two independent experiments were conducted and each sample was analyzed in 
triplicate. Each replicate was averaged and expressed as relative to the control (M12 cell line).      
A-B reports early passaged and late passaged migration assay, respectively. Observing 1.8 and 2.2 
fold increase in the movement of cells. C-D reports early passaged and late passaged invasion 
assay, respectively. Observing, a change of expression between the two passages, 1.8 versus. 0.85.  
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3.9 Discussion 
 Previous work compared the expression of miR-299-5p and miR-299-3p in miR 
array panel screens of RNA extracted from M12 versus parental P69 cell line, confirmatory single 
miR analysis and in patient samples. Conflicting results were obtained for miR-299-5p where 
panel analysis suggested it to be a tumor suppressor, no confirmatory results were obtained for 
single miR analysis and patient samples were split, two suggesting an oncomiR and two a tumor 
suppressor. Mir array panel screens are notorious for not yielding accurate expression values 
making single miR analysis imperative. Unfortunately, an error occurred in this PCR reaction so 
a single miR analysis value was not obtained at that time. In any case it was felt patient data would 
be more relevant, but as often is the case with patient samples, here too data can vary greatly due 
to the heterogeneous nature of prostate cancer and the difficulty in accurate staging of a mixed 
sample. On the other hand, results with miR-299-3p were more consistent. Although the panel miR 
array screen analysis suggested miR-299-3p might be an oncomiR, single miR analysis and all 
patient samples tested suggested miR-299-3p as a tumor suppressor.   
 To resolve these differences and investigate the role of miR-299 in prostate cancer 
it was decided to restore miR-299 expression in the M12 cell line and investigate the consequences 
on cell behavior.  For this purpose the M12 cell line was stably transformed with a precursor miR-
299 mini-gene. To our surprise this resulted in a preferential altered expression of miR299-5p with 
no increase in miR-299-3p expression and no effect on the expression of two unrelated miRNAs. 
On the one hand, this unexpected result was favorable as it permitted the analysis of altering only 
the expression of miR-299-5p alone on cell behavior not complicated by similarly altering the 
expression of miR299-3p.  The reason for the enhanced expression of only miR-299-5p could be 
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due to diverse nature of miRNAs. They are involved in a wide variety of developmental processes 
and are essential in networking and regulating gene expression [54]. A specific strand of miRNA 
is selected by the RISC complex based on the mRNA it aims to target in the cell [55]. The specifics 
of this selection process is unknown and is currently understudy in other laboratories. Our highly 
metastatic M12 cell line may possess certain mRNAs coupled with a RISC selection process that 
enables only miR-299-5p to be over produced. This analyses allowed us to proceed with an 
examination of how the altered expression of only one mature miRNA from a precursor, capable 
of generating two miRNAs, could by itself affect cell behavior. In retrospect, how the RISC 
complex accomplishes this feat would be an interesting area of future investigation.  
 Proliferation, migration, and invasion assays were conducted between the M12 
and M12+miR-299-5p cell line to determine the consequence of enhanced miR-299-5p expression 
on cell behavior. A proliferation assay carried out at 24, 48, and 72 hours’ time interval revealed 
that both cell lines were growing nearly at the same rate, except at 72 hours M12+miR-299-5p 
declined slightly. In support of this analyses, one study states that miRNAs mapped to the 
14q32.31 cluster play an important role in inhibiting cell proliferation in metastatic PCa. 
Especially, miR-299-5p at 72 hours caused cells to undergo apoptosis [44]. This could be one 
reason for the decline in cell growth observed in our M12+miR-299-5p cell line at 72 hours. Two 
sets of migration and invasion assays were carried out for M12 and M12+miR-299-5p cell lines. 
One set was conducted with earlier passaged cells and the other with later passages. Migration 
assay results varied only slightly between the two cell lines; however, results varied significantly 
for the invasion assay between different passage numbers. Cell passaging is defined as number of 
times cells have either been transferred from vessel-to-vessel [56], or merely, the number of times 
cells were split and their media changed to ensure healthy living conditions. One study reports that 
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sequences of changes in miRNA expression occurs during the tissue-culture passage [57]. Cell 
lines at high passage number experience alterations in growth rates, morphology, response to 
stimuli, protein expression and transfection efficiency compared to lower passage cells. Passaging 
cells also causes alteration in cell function such as tumorigenicity, differentiation, gene expression 
and cell signaling [56]. For our case, miR-299-5p, from the beginning, has shown variability in its 
nature. For some patient analyses it came out as an oncomiR, while for other patients it came out 
as a tumor suppressor. The fluctuation in data may have caused miR-299-5p to act in a different 
way for migratory and invasive processes. Instead of inhibiting, in the early passaged cell line, the 
M12+miR-299-5p cells migrated like oncomiR cells for both cell migration and invasion. In later 
passaged cells, the invasion assay was inhibited by miR-299-5p which could explain a shift in cell 
behavior. As mentioned earlier, cell passage number must have started to alter growth rates and 
gene expression, causing cells to migrate at a slow rate. 
 Although miR-299-5p may have behaved opposite to its nature in cell growth and 
migration, luciferase assays conducted to determine the gene expression of OPN targeted by miR-
299-5p confirmed that miR-299-5p was acting as a tumor suppressor. Initially, the luciferase assay 
was carried out between the two best OPN sites (OPN 9 and OPN 13) within its 3’UTR transfected 
into both the M12 and M12+miR-299-5p cell lines. The result were favorable and revealed that 
the expression of OPN’s 3’UTR was repressed more in the M12+miR-299-5p cell line than M12 
cell line. This suggests that miR-299-5p, stably transformed into the M12 cell line is functional 
repressing the expression of both OPNs. As mentioned above the study conducted by Shevde et 
al. also showed the expression of OPN to be repressed by co-transfecting miR-299-5p in the 
MCF10AT (breast cancer) cell line. The results of our analyses were very similar to this published 
report where in fact 30% repression was observed in our cell lines for both OPN sites while 31% 
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repression was observed in their study. However, the published is study reported repression of 
only one miR-299-5p binding site in OPN’s 3’UTR, whereas we suggested two such binding sites. 
Furthermore, to confirm miR-299-5p was indeed binding to the 3’UTR of OPN, mutation of the 
two OPN sites were prepared. To avoid any additional shift downstream of the non-mutated OPNs, 
the old sets of original OPN were shortened, without disrupting their original seed region for 
binding to miR-299-5p, hence maintaining the same mfe for both the old and new sets of non-
mutated OPN sites. Luciferase assay carried out on the new shortened sets of original OPNs and 
mutants thereof  revealed that while the same repression percentage was observed for the new sets 
of originals, a higher expression of the mutated OPNs was observed in the M12+miR-299-5p cell 
line. These analyses confirm that miR-299-5p is a proven target for the 3’UTR of OPN. Often in 
the literature luciferase assay analyses are conducted on only the wild-type binding sites versus a 
control vector with no inserted 3’UTR sequences. Here, we report not only luciferase assays 
conducted on the original OPN binding sites, but also on defined OPN mutations within the 
binding site for target seed recognition. This further confirms the analyses and ensures that miR-
299-5p is one of several miRNAs that binds to the 3’UTR OPN.  
 In conclusion, from conflicting data on miR-299-5p it is difficult to conclude in 
which condition this miRNA acts as an oncomiR or as a tumor suppressor. One possibility is that 
as PCa progresses to later stages of tumorigenesis and ultimately metastasis, miR-299-5p/3p 
switches roles and acts accordingly. Future experiments will include overexpressing miR-299-3p 
in the M12 cell line as a miR mimic. The subsequent effect on proliferation migration, and invasion 
will be measured as done here for miR-299-5p. If miR-299-3p is truly a tumor suppressor then 
cells should be less migratory and invasive. Ultimately, it will be determined how well                       
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miR-299-3p binds to its proposed target, the androgen receptor by luciferase:3UTR constructs and 
western blots with the appropriate cell extracts, since antibodies to the AR are available. 
 On the other hand, it is possible that miR-299-5p and -3p act additively or 
synergistically with each other thus results obtained with modulating the individual miRNAs may 
vary widely to what happens in vitro where both are expressed perhaps at different levels. To 
address this issue overexpressing miR-299-5p or -3p within the high of low context of the other 
maybe required to ultimately determine the consequences of altering miR-299 expression in vitro. 
Considerable work remains to address the importance of miR-299 to the progression of prostate 
cancer. 
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Chapter 4 
Determine the expression levels of the five selected messenger RNA 
targets for miR-147b, an oncomiR.  
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4.1 Introduction: 
Hsa-miR-147b is a miRNA that has constantly been found to be up-regulated in previously 
mentioned (chapter 1), cancer cell lines, human panel analyses, single-miR analyses, and in 
prostate cancer biopsy tumor samples. However, this miRNA has not been well studied in any of 
the cancers and there is limited literature that provides information regarding which mRNA(s), 
miR-147b targets.  
The precursor to miR-147b is 80 bases long, and is located on chromosome 15q 21.1 from 
45,725,248 bps to 45,725,327 bps, forward strand [59]. Similar to miR-147b is miR-147a 
(UGUGUG), which differs by only one base in the seed region of miR-147b (UGUGCG) (Table 
4-1). Studies have revealed that the expression of miR-147a inhibits cell proliferation and 
migration [62]. Moreover, miR-147a is involved in a negative feedback loop that inhibits the pro-
inflammatory response of macrophages to multiple toll-like receptor (TLR) ligands [60]. A proven 
target for miR-147a is vascular endothelial growth factor A (VEGFA), but no proven targets for 
miR-147b have yet been determined [34]. However, a very recent study discovered that miR-147a 
and miR-147b were overexpressed in left colon cancer compared to right colon tumors. This 
interesting result suggested that miR-147a and miR-147b could be relevant biomarkers for 
identifying subtypes of colon cancer [61].  
Another miRNA, miR-210 (UGUGCG), contains an identical seed region to miR-147b, 
but differs greatly for the remainder of the sequence. Based on the 6 nucleotide similarity, the 
expression of miR-147b and miR-210 could induce similar cellular effects in proliferation, 
migration and apoptosis. Despite being identical to the hexamer, UGUGCG, the divergent 
sequence (Table 4-1) between miR-147b and miR-210 appears to play an important role in 
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determining mRNA targets. Thus, each miRNA has its own unique set of mRNAs that it prefers 
to bind. 
 
Table 4-1: Sequence similarity between miR-147a, miR-147b, and miR-210. The table 
contains miRNA sequences, with the seed region highlighted in yellow.  The   underlined base is 
where the seed region for miR-147a differs with that of miR-147b and 210. 
 
 
 
[Adapted from Seashols, dissertation (2013) [34] and Bertero et al. [62]] 
 
 
 
 
 
 
 
 
 
 
 
 
Micro-RNA Sequence 
Hsa-miR-147a     GUGUGUGGAAAUGCUUCUGC 
Hsa-miR-147b GUGUGCGGAAAUGCUUCUGCUA 
Hsa-miR-210 CUGUGCGUGUGACAGCGGCUGA 
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Variation in expression due to the divergent sequences of miR-210 and miR-147b was 
observed in our panel analyses of miRNA expression in the M12 cell line compared to P69 [34]. 
While miR-210 was found to be overexpressed approximately 2-fold in the M12 cells relative to 
the P69, miR-147b showed an overexpression of approximately 17-fold. This suggests that major 
target suppression in M12 occurred due to high overexpression of miR-147b [34].   
Previous work conducted in the laboratory by Sarah Seashols, Ph.D., revealed that the 
stable expression of a miR-147b inhibitor in the M12 cell line, resulted in reduced cellular 
proliferation, and inhibition of migration, and invasiveness of M12 cells. Moreover, a reduction in 
subcutaneous tumor growth was also observed in male, athymic nude mice. The Apoptosis-
Antagonizing Transcription Factor (AATF), an activator of the cell-cycle inhibitor, p21, was 
identified as a potential target for miR-147b [34]. These results and the fact that miR-147b is 
consistently up-regulated in prostate cancer makes it an important miRNA for further study. More 
importantly, it is necessary to identify additional mRNA targets of miR-147b that could impact 
the tumorigenicity of M12 cell line as a model for prostate cancer.   
A single report was found in the literature dealing with the identification of new miR-147b 
targets. In this study, different lucferase:3’UTR constructs were co-transfected with a miR-147b 
mimic into A549 cells, a  non-small cell lung adenocarcinoma cell line, and a change in luciferase  
activity was monitored. Of the 3’UTRs from 15 different mRNAs tested, expression levels of 5 
mRNAs, i.e. ALDH5A1, COL4A2, IER5, NDUFA4, and SDHD were reduced upon restoration 
of miR-147b. Of these 5 targets, NDUFA4 seemed the most promising as it was repressed the most 
[62].  
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4.2 A brief overview of the 5 mRNA genes: 
ALDH5A1 = aldehyde dehydrogenase 5 Family, Member A1 [63] 
 ALDH5A1 is a gene located on chromosome 6p22. ALDH proteins play an important role 
in epithelial cell homeostasis. These ALDH enzymes are present in all cells and in cancer have 
been shown to protect cells against cytotoxic drugs and oxidative stress. In general, ALDH 
enzymes are responsible for oxidizing aldehydes to carboxylic acids and they play a critical role 
in physiological processes like vision, neurotransmission, embryonic development, and ester 
hydrolysis which serve as binding proteins for androgens and cholesterol [117, 118].   
COL4A2 = Collagen alpha-2(IV) chain [63] 
 COL4A2 encodes six subunits of type IV collagen and is highly conserved across species. 
It makes up a major structural component of basement membranes, and is associated with cell 
adhesion and migration. The C-terminal part of the protein, known as canstatin, is an inhibitor of 
angiogenesis and tumor growth [64]. One study reported that the loss of PDEF an epithelium-
specific Ets transcription factor in prostate cancer caused the gain of COL4A2 and its family of 
genes, hence promoting cell migration and invasiveness [65].  
IER5 = Immediate early response 5 [63] 
 IER5 has been known to be induced by gamma-ray radiation and plays a role in cell death 
caused by radiation. It has been reported, that IER5 inhibits the transcriptional expression of 
Cdc25b, which is a co-activator of the androgen receptor, causing proliferation and migration of 
leukemia progenitor cells to be reduced. Since androgen receptor promotes prostate cancer cell 
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growth, inhibiting its co-activator may reduce proliferation and migration of prostate cancer cells 
as well [66].  
SDHD = Succinate dehydrogenase complex subunit D [63]    
 SDHD is a part of mitochondrial subunit of oxidative phosphorylation (OXPHOS) 
complex II, and is localized in the inner member of mitochondria. Mitochondrial metabolism 
controls the life of cancer cells and their proliferative properties. Thus, mutation of mitochondrial 
genes can contribute to tumorigenicity and increase reactive oxygen species (ROS). In fact a 
variety of mitochondrial DNA and control region mutations have been reported in prostate cancer 
[67]. 
NDUFA4 = NADH dehydrogenase 1 alpha subcomplex 4 [63] 
NDUFA4 is an accessory subunit of the mitochondrial membrane respiratory chain NADH 
dehydrogenase complex I, which does not undergo catalysis. Electrons are transferred from NADH 
to the respiratory chain. Although a direct role of NDUFA4 has not been found in cancer, the loss 
of OXPHOS genes, such as NDUFA4 itself, have been shown to contribute to the ability of cancer 
cells to be self-sufficient and less dependent on OXPHOS [68]. Deficiency in OXPHOS is 
associated with the decreased availability of ATP, which promotes malignancies and tumor cell 
expansion [69]. Therefore, it is sufficient to believe that in prostate cancer, part of tumor growth 
can be held responsible to mutation of mitochondrial genes.  
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4.3 RNAhybrid analyses for miR-147b and its targets 
To assess the binding strength between miR-147b and its 5 mRNA targets, the miR-147b sequence, 
obtained from miRBase [25], and the 3’UTR sequences of each of the proposed 5 mRNA targets  
obtained from National Center of Biotechnology Information (NCBI) (Table 4-3) were submitted 
to analysis via RNAhybrid software [37]. The result of this analyses indicated that miR-147b had 
a strong binding affinity to all of its mRNA targets (Table 4-2). It will be interesting to determine 
how well the results of these proposed in silico matches correlate with results obtained from 
expression experiments conducted in vitro.  
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ALDH5A1 
 
MFE: -22.4 kcal/mol 
position  148 
ALDH5A1 5' G   A        GAG  CUUGAAUUUCAG    C  3' 
           UAG AGAGGCAU   CC            GCAC      
           AUC UCUUCGUA   GG            CGUG      
miRNA  3'     G        AA                   UG 5' 
 
 
COL4A2 
 
MFE: -25.7 kcal/mol 
position  99 
COL4A2 5' A  C        G      UG  C 3' 
           AG CAGGAGCA   CC C  GC     
           UC GUCUUCGU   GG G  UG     
miRNA  3' A           AAA  C UG    5' 
 
 
IER 5 
 
MFE:  -34.5 kcal/mol 
position  272 
IER5   5' G   CA   GU              G 3' 
           GGC  GGA  GGCGUUUCCGCACA     
           UCG  UCU  UCGUAAAGGCGUGU     
miRNA  3' A                        G 5' 
 
 
SDHD 
 
MFE:  -21.5 kcal/mol 
position  608 
SDHD   5' A     AUAAAUU U            A 3' 
            AGUA       G UAUUUUCGCACA     
            UCGU       C GUAAAGGCGUGU     
miRNA  3' A     CUU                  G 5' 
 
 
NDUFA4 
 
MFE: -29.4 kcal/mol 
position  41 
NDUFA4 5'   C       CACA        A 3' 
             CAGAAGC    UCCGCACA     
             GUCUUCG    AGGCGUGU     
miRNA  3' AUC       UAA         G 5' 
 
 
Table 4-2: Binding of miR-147b to its 5 mRNA targets. The sequences of miR-147b and 5 
mRNA were submitted to RNAhybrid software [37] to assess their binding strength. The resulting 
low mfe values, indicate a strong binding between mRNA 3’UTRs and miR-147b. 
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4.4 The goals of this research 
After evaluating the relevance of each mRNA, mentioned above, in prostate cancer and in 
RNAhybrid software [37]; the goals of this research are as follows:  
1. Request the 5 mRNA constructs as luciferase:3’UTR constructs from Bertero, et al., from 
Insitut de Pharmacologie Moléulaire et Cellulaire (IPMC) located in France. Perform 
standard cloning procedures.  
2. Transfect these constructs into the M12 cell line, which naturally expresses miR-147b (17-
fold overexpression compared to the parental p69 line) as a model for prostate cancer 
progression). 
3. Perform luciferase assays on these transfection to verify miR-147b: mRNA regulation in 
M12s as a surrogate for prostate cancer cells. It is expected that luciferase activity will be 
reduced for mRNAs if truly targeted by miR-147b.  
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4.5 Methods and Materials: 
As previously reported in chapter 2 and 3, cells were cultured, the 5 mRNAs were transfected into 
the M12 cell line, and luciferase assay were performed.  
The only step that differs for this chapter is the:  
DNA Synthesis and cloning 
Plasmid DNA samples of the 5 mRNA targets, ALDH5A1, COL4A2, IER5, NDUFA4, and 
SDHD, were obtained from Bertero et al. [62] on whatman filter paper. Plasmid DNA came cloned 
into PsiCHECK-2 vector cut with Xho1 and Not1 sites. Whatman filter paper was cut along the 
lines, where the plasmid was spotted, and small pieces of the paper were suspended into 50uL of 
TE or Elution Buffer in an eppendorf tube. The solution was squashed and vortexed vigorously, 
ensuring elution of the plasmid. The solution was stored at 4°C for a minimum of 30 min and used 
for transformation into DH5α E. coli cells. Aliquots of 50uL or 100uL of the transformants were 
plated on agar plates and selected with the drug ampicillin. The forward and reverse primer 
sequences and length of each of the 5 mRNA’s 3’UTR is listed in Table 4-3. The standard miniprep 
following the manufacturer’s protocol (Qiagen) was performed and DNA was sent to VCU-NARF 
[58] for confirmatory sequencing. Upon confirmation, midiprep DNA (Qiagen) based on the 
manufacturer’s protocol was performed to extract a plasmid suitable for transfection. For 
transfections only midiprep plasmid products were used due to high purity and concentration of 
DNA obtained. 
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Table 4-3: Sequences of the 5 mRNA targets of miR-147b. Accession numbers were obtained 
from the NCBI database. Length of the 3’UTR indicates the total length of the 3’UTR within 
which the miR-147b match was found.  Forward and reverse primers were obtained from Bertero 
et al. [62]. 
 
 
 
 
 
 
 
 
NCBI -
Accession # 
Name of 
mRNA 
Length of 
3’UTR (bp) 
Forward primer Reverse primer 
NM_001080.3 ALDH5A1 400 CGACCTGAGCCTGAGTAAGTGG AACCCAGAATAACCACAAGAT
GTAAGTG 
 
NM_001846.2 COL4A2 288 GGAATTTGCATCCAGCAGCAGCAC CCTCTGGCCACGGCTGGC 
 
NM_016545.4 IER5 444 GGCTCATTGGAAGAGGACGATCG TGCGGGGAAGCAAAGGACCG 
 
NM_003002.3 SDHD 666 GGTGGACAGCCTTCTTCTCTTAATC CATAGAATACATTTTCACATTA
GAGATTCCC 
NM_002489.3 NDUFA4 420 GAAATGTTTCACTATAACGCTGCTT
TAG 
CATAGAATACATTTTCACATTA
GAGATTCCC 
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4.6 RESULTS: 
Luciferase assays were conducted on transient transfections of each of the 5 mRNA 
luciferase:3’UTR constructs described above compared to the empty psiCHECK-2 vector,  in the 
M12 cell line, which expresses considerable miR-147b. As anticipated, luciferase activity from 
each of the constructs was greatly suppressed as compared to the empty vector. The expression of 
ALDH5A1 was reduced 31%, COL4A2 reduced 59%, IER5 reduced 47%, NDUFA4 reduced 
31%, and SDHD reduced 45% (Figure 4-1). Similar assays were performed by Bertero et al. [62], 
in the A549, lung cancer cells yielding the following results: ALDH5A1 reduced 20%, COL4A2 
reduced 10%, IER5 reduced 32%, NDUFA4 reduced 41%, and SDHD reduced 5% [62]. Although 
NDUFA4 was suppressed more in the A549 cells, the majority of these luciferase:3’UTR 
constructs i.e. ALDH5A1, COL4A2, IER5 and SDHD, were suppressed more in our prostate 
cancer model M12 cell line than in the A549 cell line. Among the 5 mRNAs, the greatest 
suppression was observed for COL4A2 and SDHD, followed by IER5, while, the same 
suppression was observed for NDUFA4 and ALDH5A1.  
A comparison between mfe values obtained from RNAhybrid software [37] (Table 4-3), 
and luciferase activity (Figure 4-1) assay revealed no correlation between these two types of 
analyses. For instance, the IER showed the most favorable mfe (-34.5 kcal/mol); however, the 
greatest repression was observed for COL4A2. Similarly, the least favorable mfe was observed for 
SDHD, but its repression level was greater than either ALDH5A1 or NDUFA4. Although 
expression of ALDH5A1 and NDUFA4 yielded the same level of repression, their mfes were not 
alike, i.e., one was -22kcal/mol and other was -29 kcal/mol, respectively (Table 4-4). 
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Figure 4-1: Luciferase assay results for transfection of the psiCHECK-2 vector containing 
the 3’UTR of 5 mRNA targets of miR-147b into the M12 cell line compared to empty vector. 
A total of 2.5x104 M12 cells per 500uL were plated in the 24-well plate. The 5 mRNA targets of 
miR-147b were transfected into the M12 cell line, 24-48 hours later cells were lysed, and luciferase 
activity was measured. The firefly luciferase activity and stop & glo (renilla) were measured at 
wavelengths of 560 nm and 480 nm, respectively. Firefly luciferase expression is reported 
normalized to renilla luciferase activity, while fold change values are reported relative to the empty 
vector. Each mRNA sample was measured in triplicate with a p value ≤ 0.05. Among the 5 
mRNAs, the greatest suppression was observed for COL4A2 followed by IER5 and SDHD at a 
similar rate, with ALDH5A1 and NDUFA4 yielding similar repression values at the lowest level.  
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Table 4-4: Results obtained from RNAhybrid software, and luciferase assay. A clear 
correlation between the two analyses is not observed. The lowest mfe was observed for IER5, 
however the highest repression was observed for COL4A2. Similarly, ALDH5A1 and NDUFA4 
repressed at the same level but their mfes differed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mRNA Mfe from RNAhybrid  
(kcal/mol) 
Repression 
percentage 
 (%) 
ALDH5A1 -22.4 31 
COL4A2 -25.7 60 
IER5 -34.5 47 
SDHD -21.5 45 
NDUFA4 -29.4 31 
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4.7 Discussion: 
MiR-147b appears to function as an oncomiR in prostate cancer. Its high level of 
expression has been consistently observed in every type of analyses the Zehner laboratory has 
conducted [34]. Human panel miR arrays, single-miR analysis, and prostate cancer biopsy 
samples have confirmed miR-147b to be an oncomiR. Reduced cell proliferation, migration and 
invasion were observed when miR-147b was inhibited in the M12 cell line [34]. Thus an 
investigation into those targets driving a tumorigenic outcome is important. At the time there was 
a limited literature on proven miR-147b targets and especially not in prostate cancer. Although 
some bioinformatic tools had suggested potential targets for miR-147b, there was no research, to 
validate a regulatory role. Despite limited sources, Sarah Seashols, Ph.D., was able to identify a 
new target for miR-147b as AATF.  
Each miRNA is proposed to target hundreds of mRNAs and probably cancer results from 
the targeting of several mRNAs not just a change in expression of a single mRNA. Thus, it became 
important to identify other mRNA targets whose change in expression via miR-147b regulation 
could contribute to prostate cancer progression. .  
 A recent paper disclosed 5 new mRNA targets, ALDH5A1, COL4A2, IER5, SDHD, and 
NDUFA4 as potential targets for miR-147b in the A549 lung cancer cell line [62]. Here we show 
these same 5 mRNAs are relevant targets for miR147b regulation in prostate cancer as well, but 
not necessarily at the same level. Some mRNAs were suppressed more than others and did not 
exhibit a direct correlation to those results obtained in the A459 lung cancer cell line. Because 
miRNAs are tissue specific in their expression, it is expected that their resulting effect on target 
regulation will differ in different cell lines as seen here. One reason for this can be the selective 
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presence or lack of other miRNAs in the M12 cell line, which compete with mir -147b for target 
binding. In the latter case, the lack of competitive miRNAs could favor the mir147b binding and 
yield a greater repression of the mRNA targets.  
Transfection of the 3’UTRs of ALDH5A1, COL4A2, NDUFA4, SDHD, and IER5, in the 
M12 cell line showed a reduction in the luciferase activity. Most repression in the activity was 
observed by COL4A2, followed by IER5, SDHD, NDUFA4, and ALDH5A1. SDHD, NDUFA4, 
and ALDH5A1 are mitochondrial enzymes that are crucial for normal tricarboxylic acid cycle and 
electron transport chain (ETC) activity. NDUFA4 is a subunit of ETC complex I and SDHD is a 
subunit of ETC complex II [116]. COL4A2 is associated with cell adhesion and migration [65], 
and IER5, is induced by gamma-ray radiation, which causes cell death by radiation [66]. Down-
regulation of these mRNAs indicates that miR-147b alters mitochondrial and apoptotic function 
in the M12 cell line, which facilitates the progression of tumor. To support this analyses, a similar 
study was performed by Grosso et al. with miR-210 in the A549, lung cancer cell line. MiR-210 
was found to be up-regulated in this cell line, and luciferase assay showed that miR-210 inhibited 
the expression of COL4A2, ALDH5A1, NDUFA4, and SDHD, confirming an alteration to the 
mitochondrial respiration in the A549 cells. To further confirm their analyses, electron microscopy 
performed on the cells containing miR-210, revealed a re-arrangement of cristae in the 
mitochondria compared to the normal mitochondria morphology [70]. In our human panel analyses 
both miR-147b and miR-210 were up-regulated, and classified as oncomiRs. As mentioned above, 
these miRNAs share a common seed region, hence they target some of the same mRNAs. These 
miRNAs also induce similar cellular effects in term of proliferation, migration and apoptosis [62]. 
Similarly just like miR-210, our luciferase assay also confirms that miR-147b modifies normal 
 
 
 
97 
 
mitochondrial and apoptotic behavior of cells, and promotes tumorigenesis. Overall, these 
luciferase:3’UTR assay results validate a direct  interaction between miR-147b and all its targets. 
RNAhybrid results did not completely correlate with the luciferase assay results. The 
lowest mfe was observed for IER5, however the most repressed luciferase activity was observed 
for COL4A2. The highest mfe was observed for SDHD, but it repressed better than ALDH5A1 or 
NDUFA4. Even after observing the same repression rates for ALDH5A1 and NDUFA4, their 
mfe’s differed, in fact NDUFA4 had a lower mfe than ALDH5A1. Although RNAhybrid [37] is a 
useful tool for predicting the binding strength of a miRNA to mRNA interaction, this software 
does not take into account the cell lines in which the repression activity will be measured. MiRNAs 
are cell specific, hence our M12 cell line may contain other miRNAs that may have a better binding 
affinity to the 3’UTR of the 5 mRNA targets, than miR-147b. On the other hand, they may lack 
other competing miRNAs with a better binding affinity to any one of these targets, giving miR147b 
a regulatory advantage not duplicated in the A459 cell line. Overall, RNAhybrid is a great tool to 
predict an interaction between the miRNA and its target mRNA, but experimental validation, is 
required to validate such an interaction and the consequences thereof to cell behavior.   
In conclusion, the results of luciferase assay confirm a direct binding between all 5 mRNAs 
and their target, miR-147b. However, the computational analyses did not confer with luciferase 
assay analyses. Conveying, that miRNAs are specific to each cell line, and their behavior may not 
always adhere to the behavior observed in computational analyses.  
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Chapter 5 
A bioinformatics approach to identify microRNAs present in the 
body fluids of normal subjects.  
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5.1 Introduction:- 
 The discovery of miRNAs is an emerging field in cancer research with potential novel 
techniques for diagnoses and therapy [71]. MiRNAs are small regulatory RNA molecules that 
regulate the activity of specific mRNA targets and play an essential role in physiological and 
pathological processes [72], such as gene-expression and aberrant expression in the pathogenesis 
of cancer, cardiac, immune-related, and other diseases [73]. While research on identifying tumor 
specific miRNA has been ongoing for more than a decade now, miRNAs have also been discovered 
in serum, plasma, and other body fluids [73]. A study performed by Chen et al. [75] demonstrated 
by using a Solexa Sequencing platform that by extracting RNA from the serum, they could identify 
unique miRNA expression profiles, for lung cancer, colorectal cancer, and diabetes patients 
compared with healthy subjects. This study also revealed that miRNA expression profiles differed 
between serum and blood cells of lung cancer patients, while similar miRNA expression profiles 
were seen in the serum and blood cells of healthy subjects. Overexpression of specific miRNAs 
within a tumor can be observed in body fluids of patients; therefore, involvement of miRNAs in 
early tumorigenesis, tumor progression and metastasis could serve as diagnostic or prognostic 
markers for a variety of cancers [71]. Novel or improved approaches for detecting common 
epithelial malignancies are required to reduce major health issues caused by cancer. Although 
conventional strategies for blood-based biomarker discovery using proteomic technologies have 
shown promise, the development of clinical methods to identify biomarkers, for early tumor 
detection, in cancer still requires improvement [74, 75]. 
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5.2 Stability of miRNAs: 
Decades ago when miRNAs were newly identified, many investigators predicted that extracellular 
RNA could not survive in blood due to presence of potent ribonucleases [97]. However, slowly 
this misconception faded as additional studies revealed that circulating extracellular RNA in serum 
is protected from plasma RNAse activity [98]. Chen et al [75] showed that serum and plasma 
contain a large number of miRNAs and these miRNAs remain stable after being subjected to severe 
conditions such as boiling, very low or high pH, extended storage, and 10 freeze-thaw cycles that 
would normally degrade most RNAs. Many theories have attempted to explain the possible 
mechanisms responsible for such high quality stability. One theory suggests that RNA present in 
plasma is protected by inclusion in lipid or lipoprotein complexes [97]. Other reports have 
suggested the secretion of mRNA and miRNAs across cell membranes either in microvesicles or 
in small membrane vesicles of endocytic origin called exosomes [99, 100].  A study performed by 
Taylor et al demonstrated that miRNA contained in tumor exosomes are functional and can 
suppress the mRNA that encodes signal transduction components within T-cells. [101]. Skog et 
al, demonstrated that exosomes secreted by gliobastoma cells containing mRNA, miRNA and 
angiogenic proteins are taken up by normal brain microvascular endothelial recipient cells. The 
messages delivered by tumor-derived exosomes are further translated by these recipient cells to 
stimulate proliferation of a human glioma cell line [102]. Prior reports indicate that cancer patients 
have elevated levels of tumor-derived exosomes in plasma compared to non-cancer controls. 
Although normal cells within peripheral circulation can contribute to exosome population, the 
primary source of circulating exosomes in cancer patients is thought to be from the tumor [103]. 
Although the presence of miRNA in exosomes can explain their stability in serum, other reasons 
for stability can be due to protection by chemical processes or associations with protein complexes.  
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Currently there is a lack of an established endogenous miRNA control for normalization in 
plasma or serum. The most common control used to normalize miRNA for qRT-PCR data is U6 
small nuclear RNA (RNU6B); however, this RNA was found to be less stably expressed than miR-
93, miR-106a, miR-17-5p, or miR-25 in serum. [104]. Thus additional studies are necessary for 
the identification of an accurate normalization control for each type of cell, tissue or body fluids 
to be studied.  
5.3 Identifying miRNAs in body fluids:  
An important aspect of miRNAs is the possibility that these molecules are secreted, circulate and 
subsequently affect cellular behaviors elsewhere in the body producing favorable conditions for 
disease progression. In 2008 Lawrie et al. introduced miRNAs as a new class of biomarkers in 
serum. In this study miRNAs were purified from patient serum using the Trizol reagent and certain 
miRNAs were quantified using Taqman based PCR. Results showed that the expression pattern of 
miR-155, miR-210 and miR-21 distinguished large B-cell and lymphoma patients from normal 
people [80]. Several other studies have shown miRNA expression profiles related to tumor 
classification. Mitchell et al found that by measuring serum levels of miR-141, they could 
distinguish patients with prostate cancer from healthy subjects [74]. Similarly Chen et al 
demonstrated that levels of miR-25 and miR-223 were more elevated in cancer patients than those 
of healthy individuals [75]. Ng et al showed that miR-92 was more significantly increased in 
colorectal cancer than in gastric cancer or normal subjects [105]. Wong et al reported that miR-
184 showed significantly higher expression in tongue squamous cell carcinoma cells than in paired 
normal cells [106]. While these studies identified miRNAs expression level in plasma or serum, 
one report evaluated miRNA expression levels in urine, breast milk, tears, saliva, cerebrospinal 
fluid, seminal fluid, amniotic fluid and other fluids. These body fluids were obtained from women 
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in different stages of pregnancy or in patients with different urothelial cancers. The results of this 
study demonstrated that miRNAs were present in all body fluids, several of the abundant miRNAs 
were common among multiple fluid types while others were enriched in specific fluids. The overall 
conclusion of this study was that although miRNAs were ubiquitous to all biological fluids, 
specific compositions components at different concentrations were observed for each body fluid. 
These findings are important because it presents a useful correlation between specific miRNAs in 
body fluids and various diseases. Hence, this study provides the insight that miRNAs could serve 
as useful biomarkers in clinical usage [76].  
 5.4 Aim of this research: 
The purpose of this research is to identify miRNAs present in six body fluids of healthy 
male and female volunteers: venous blood, menstrual blood, vaginal fluid, semen, saliva, and feces 
through a next-generation sequencing approach. In our case, such miRNAs will be first identified 
in normal healthy human body fluids. The result of this will not only help us determine prominent 
miRNAs in body fluids that could serve as biomarkers, but miRNAs that can act as positive 
controls against which the content of prostate cancer patient body fluids can be compared. It is 
essential to determine which miRNAs are found normally in body fluids attained from healthy 
people; so that in analyzing prostate cancer patients’ body fluids, the loss or gain of miRNAs could 
be diagnostic of disease.   
The advantage of using RNA sequencing versus miR panel array analysis is that by the 
former all possible, including novel, miRNAs will be identified. Screening of microarray panels 
are only able to yield data on those already known and included miRNAs. The promise of RNA 
sequencing is that all miRNAs both known and unknown can be deduced and quantitated. 
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Moreover, the analysis of microarray panels has already been done in the literature, but RNA 
sequencing of all body fluids relevant to forensic science or to prostate cancer has not yet been 
reported. Hence, we propose that this is the more encompassing study that should be done. 
Previous laboratory work performed by students within the Forensics Science and 
Biochemistry Departments at VCU-Medical Center under the guidance of Drs. Sarah Seashols and 
Zendra Zehner, included extracting RNA from 4 different donors for each of the body fluids 
analyzed. After evaluating quality and quantity of the acquired RNA using the Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA [34]) and NanoDrop ND-2000 Spectrophotometer 
(Thermo-Fisher Scientific, Inc; Waltham, MA [34]), the required concentration of RNA 
(100ng/uL), was sent off to the VCU-NARF core [58] for RNA sequencing using the Illumina-
HiSeq platform. The Illumina-HiSeq, RNA sequence data (RNA-SEQ), was analyzed using the 
CLC Genomics workbench version 7.0.4 and annotated against miRBase (v.20, 2013) [13].  
5.5 The CLC genomics workbench: 
CLC is a high-throughput genomic software that supports features such as de novo 
assembly, where it offers comprehensive support for a variety of data formats such as the 454 FLX 
system, Illumina Genome Analayzer, Illumina HiSeq, HiScan, MiSeq sequencing systems, SOLiD 
system, and Ion Torrent system. Mapping of both short, long and paired reads can be done in this 
software. RNA-SEQ analyses, in which we are interested is, based on reference genome or mRNA 
sequencing reads. This workbench is able to calculate expression levels and determine novel exons 
or miRNAs. It provides core tools to trim the adapter sequences on next generation sequencing 
data, provides transcriptomic analyses such as extract and count, common occurring sequences, 
and annotate and merge data against the desired database or reference genome [79].  
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5.6 Methods to curate RNA-SEQ data in the CLC genomic workbench: 
A total of 6 body fluids were analyzed: venous blood, menstrual blood, vaginal fluid, 
semen, saliva, and feces. Four samples per body fluid were sent off for Illumina-HiSeq sequencing; 
thus a total of 24 data files were obtained for analyses. In general for Illumina-HiSeq sequencing, 
a population of RNA is first converted into a library of cDNA fragments with adapter sequences 
attached to one or both ends. Through amplification process each molecule is sequenced in a high-
throughput manner to obtain sequences from either, one end (single-end sequencing) or both ends 
(pair-end sequencing). Sequences generated are usually 70-200bp long in length [77].  In our case 
only single-end sequencing data was generated, due to the panel size of the cDNA template and 
each sequence in the RNA-SEQ data consisted of a 5’ primer sequence, 5’ adapter sequence, 
miRNA sequence, 3’adapter sequence, barcode, and 3’ primer sequence (Figure 5-1).  
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Figure 5-1: The final PCR product and the location of each adapter sequence. Once RNA has 
been sequenced the final PCR product consists of the following, a 5’ small RNA sequencing 
primer, 5’ adapter sequence (green), miRNA insert (blue), 3’ adapter sequence (purple), barcode 
(black), and multiplex index read sequencing primer. 
[The figure idea adapted from the New England BioLabs manual [107]]  
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To annotate the RNA-SEQ data, three major steps in the CLC genomic software were 
applied: (i) Trimming off the adapter sequences, (ii) extract and count sequences that occurred 
more than once and (iii) annotate against a miRNA database, for our purpose miRBase (v.20, 2013) 
database was used [13]. 
(i) Trimming off the adapter sequences: 
Fastq formatted files were imported into the CLC genomic software, single-end-sequence 
option was selected and NCBI/Sanger or Illumina 1.8 pipeline was used. Before trimming off the 
adapter sequences a trim adapter sequence file was created, where 5’adapter sequence 
(5’GTTCAGAGTTCTACAGTCCGACGATC 3’), reverse complimented 3’adapter sequences 
(5’AGATCGGAAGAGCACACGTCT 3’) were recorded and plus and minus strands were selected, 
respectively. For each adapter sequence the remove adapter option was selected. This option 
removes adapter sequences and all the nucleotides 5’ of the match, while preserving everything 3’ 
end of the match. The same action was applied for the 3’ adapter sequence, where together with 
the adapter sequence all the nucleotides 3’ of the match were removed and everything 5’ end of 
the match was preserved.  The alignment score [14] for each of the adapter sequence was set as: - 
mismatches = 2, gap-cost = 3, minimum score for matches found within the read was set to 15, 
and minimum score for end matches was set to 4. Examples of how mismatches and gap-costs 
were calculated are shown in figure 5-2 [79]. Reads were trimmed based on quality score of 0.05 
and maximum of 2 ambiguous nucleotides were removed. Reads below length 15 and above length 
1000 were discarded.  
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Figure 5-2: Examples showing how mismatches and gap-costs are calculated based on Smith-
Waterman algorithm. A list of adapter sequence in the CLC genomic software has to be created 
in order to perform the trimming step on the reads from RNA-SEQ data. When a match on the read 
is found a set of scoring thresholds are adjusted for each adapter sequence. The first step includes 
setting the costs of mismatches and gaps. According to the Smith-Waterman algorithm [78] a 
match is rewarded one point, this score cannot be changed. A mismatch costs 2 points and a gap, 
such as insertions or deletions, costs 3 points. Mismatch based on internal matches: for example 
A) a total of 11 matches was found (11x 1 = 11), with 2 mismatches (2 x 2 = 4), hence the alignment 
score equals to 11 - 4 = 7. Mismatches found on end indicates a match found on either end of the 
read. Example B) shows that 9 matches were found with 1 gap (1x 3 =3) hence the total alignment 
score was 6 for the end match.  
[The figure idea adapted from the CLC genomic software manual [79]] 
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(ii) Extract and count trimmed reads: 
This step can be performed either on the original (non-trimmed) fastq file or trimmed file 
generated from the trimming off the adapter step. If conducting analyses on the original file, the 
adapter trimming step is selected, else if analyzing the trimmed file, that option is left blank. Reads 
below length 15 and above length 55 were discarded. Minimum sample count was equaled to 1. 
Minimum sampling counts is number of small RNAs tags needed to count the reads. Counting of 
the re-occurring reads is based on perfect matches found between sequences. Therefore, a 
threshold of 1 indicates a lot of unique tags are created, while high threshold becomes selective 
and only few tags are generated.   
(iii) Annotation and merge counts: 
The file generated from the extract and count step is used for the annotation and merge 
count step. Before this step was performed, miRbase release 20 database was downloaded in the 
CLC genomic software. Together with miRbase v.20, other miRNA database can also be 
downloaded and selected. H. sapiens species was selected as the organism; however more than 
one species can also be selected. The order in which the species are selected is important because 
the tags annotate iteratively based on the order specified. Next, the parameters for alignment of the 
tags against the annotation sources were set as: additional upstream bases = 2; additional 
downstream bases = 2; missing upstream bases = 2; and missing downstream bases = 2; these 
parameters are set as default by the software for only miRbase annotation source. Additional 
upstream and downstream bases defines how many bases the tag is allowed to extend the annotated 
mature region at 5’ end or 3’end and can still be identified as mature. Missing upstream and 
downstream bases indicate how many bases a tag is allowed to miss either 5’end or 3’ end compare 
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to the annotated mature region and still be identified as mature. Maximum mismatches was set to 
2. Next, the types of file to be generated were selected.  
5.7 RESULTS: 
The types of files selected to be generated from the annotation and merge count steps were 
as follows: a) Annotated file- which contained information such as small RNA sequence, length 
of those sequences, count, name of the miRNA, match type as in whether the sequence was 
qualified as mature 5’, mature 3’, mature 5’ or 3’ sub, mature 5’ or 3’ sub variant, and mature 5’ 
or 3’ super or super variant and mismatches; b) annotated grouped sample- this is a file where all 
the mature 5’ or 3’, sub/sub variants/super/super variants are grouped together and total count is 
shown;  and a summary report where a summary of how many sequences were annotated and the 
percentages were reported. Tables 5-1 A-F represents the data generated from trimming off the 
adapter sequence step. For the most part 74-99% of the adapter sequences were removed, 
indicating that the majority of the adapter sequences were successfully trimmed off.   
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Table 5-1A: Results of trimming off the adapter sequences from reads contained in the RNA-
SEQ data obtained for venous blood.  
 
 
Table 5-1B: Results of trimming off the adapter sequences from reads contained in the RNA-
SEQ data obtained for menstrual blood. 
 
 
 
 
 
Body Fluid Total 
number of 
reads 
Average 
length before 
trimming 
Number of 
reads after 
trim 
Average 
length after 
trim 
Percentage 
trimmed 
V.Blood_7309 1,957,364 91.7 1,767,370 24.6 90.29% 
V.Blood_7311 1,737,441 90.8 1,578,616 23.9 90.86% 
V.Blood_7318 2,381,563 90.9 2,134,571 24.2 89.63% 
V.Blood_7319 2,014,376 90.8 1,807,780 24.9 89.74% 
Body Fluid Total 
number of 
reads 
Average 
length before 
trimming 
Number of 
reads after 
trim 
Average 
length 
after trim 
Percentage 
trimmed 
MB_7329_Day2 595,548 97.5 561,540 31.4 94.29% 
MB_7318_Day3 1,039,921 93.0 925,872 27.8 89.03% 
MB_7315_Day6 1,983,903 94.5 1,771,937 30.2 89.32% 
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Table 5-1C: Results of trimming off the adapter sequences from reads contained in the RNA-
SEQ data obtained for vaginal fluid. 
 
 
Table 5-1D: Results of trimming off the adapter sequences from reads contained in the RNA-
SEQ data obtained for semen. 
 
 
 
 
Body Fluid Total 
number of 
reads 
Average 
length before 
trimming 
Number of 
reads after 
trim 
Average 
length after 
trim 
Percentage 
trimmed 
Semen_7311 1,170,387 98.1 1,117,742 31.3 95.5% 
Semen_7322 362,993 97.7 349,011 31.6 96.15% 
Semen_7520 369,643 98.1 366,434 31.9 99.13% 
Semen_9602 482,072 97.8 457,482 31.8 94.9% 
Body 
Fluid 
Total 
number of 
reads 
Average length 
before 
trimming 
Number of 
reads after 
trim 
Average 
length after 
trim 
Percentage 
trimmed 
VF_7314 476,369 99.6 467,108 34.1 98.06% 
VF_7315 563,933 93.5 481,684  29.6 85.42% 
VF_7319 552,911  92.0 467,583 27.9 84.57% 
VF_7321 3,511,331   97.8 3,353,973 32.4 95.52% 
 
 
 
112 
 
Table 5-1E: Results of trimming off the adapter sequences from reads contained in the RNA-
SEQ data obtained for saliva. 
 
Table 5-1F: Results of trimming off the adapter sequences from reads contained in the RNA-
SEQ data obtained for feces. 
 
 
 
 
 
 
Body Fluid Total 
number of 
reads 
Average 
length before 
trimming 
Number of 
reads after 
trim 
Average 
length after 
trim 
Percentage 
trimmed 
Saliva_7319 1,501,694  95.0 1,351,059 30.1 89.97% 
Saliva_7321 1,055,656  95.0 1,006,329 29.6 95.33% 
Saliva_7322 1,379,499  99.3 1,348,952 33.7 97.79% 
Saliva_8425 1,986,277  98.4 1,931,595 32.6 97.25% 
Body Fluid Total 
number of 
reads 
Average 
length before 
trimming 
Number of 
reads after 
trim 
Average 
length after 
trim 
Percentage 
trimmed 
Feces_7318 1,717,555  91.3 1,363,578 27.8 79.39% 
Feces_7319 1,452,225  93.5 1,265,847 28.9 87.17% 
Feces_8401 1,420,982  96.3 1,287,695 32.0 90.62% 
Feces_8407 2,471,044  88.5 1,831,558 25.1 74.12% 
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The annotation results varied widely among each body fluid, blood annotated 78%, menstrual 
blood annotated 4.4%, vaginal fluid annotated 1.3%, semen annotated 8.8%, saliva annotated 
1.3%, and feces annotated only 0.20% (Table 5-2).  
 
Table 5-2: The percentage each body fluid was annotated against the miRBase database. The 
four files per body fluid were averaged together. Thus values are reported here as an average of 
total reads after the extract and count step and an average of total reads annotated.  
Body Fluid Average number of 
reads after extract 
and count 
Average number of  
reads annotated 
against miRBase 
Percent annotated 
(%) 
Venous blood 1,703,867 1,321,778 
 
77.58 
Menstrual blood 1,027,420 45,095 4.39 
Vaginal fluid 1,183,853 15,295 1.29 
Semen 568,640 49,781 8.75 
 
Saliva 1,398,650 18,377 1.31 
Feces 1,422,408 2,804 0.20 
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Aforementioned, the annotated grouped file contained miRNAs that were classified as either 
mature 5’ or mature 3’. When RNAase III enzyme Dicer with its cofactor TRBP, snips off the 
loop of the pre-miRNA, a double stranded RNA duplex approximately 18-24 nucleotides in 
length is released. This double stranded RNA is further incorporated into RNA-induced silencing 
complex (RISC) to help retain a mature miRNA. Depending on the tissue, cell and the mRNA a 
miRNA targets, either a mature 5’ strand or mature 3’ strand is produced. Similarly, CLC 
genomic workbench, based on the types of cells found in each body fluid, classified each 
miRNA as either mature 5’ or mature 3’. Henceforth, the annotated data, represented as a list of 
abundant and unique miRNAs found in each body fluid (Table 5-4), and graphs representing 
common miRNAs found within each body fluid (Figure 5-3), was also organized in a similar 
manner.  
Table 5-4 and figure 5-3 A-L reported below show that there are many common miRNAs found 
in the body fluids analyzed for this research. To name some of the most common mature 5’ 
miRNA to occur within all body fluids is miR-21. Second most common miRNA to occur in all 
body fluids except semen is miR-451a. MiR-486 and miR-486-2 have always occurred together 
in venous blood, menstrual blood and feces. While miR-26a-1 and miR-26a-2 have also occurred 
together in blood, semen, and feces. MiR-30d was also present in all body fluids except 
menstrual blood and vaginal fluid. MiR-99a was found in menstrual blood, vaginal fluid, and 
semen, while miR-205 was found in menstrual blood, venous blood, and saliva.  To name some 
of the common mature 3’, miR-101-1, miR-101-2, and miR-22 occurred in all body fluids. MiR-
148a occurred in all body fluids except venous blood. MiRs-200a, 200b and 200c occurred 
together in menstrual blood, vaginal fluid, and semen. MiR-103a-1 was found in venous blood, 
menstrual blood and feces. MiR-203a was found in all body fluids except venous blood, and 
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semen. MiR-27b was found in all except venous blood and feces. MiRs-363, 92a-1, 92a-2 were 
found in venous blood and feces, except miR-363 was also found in semen. A compiled version 
of miRNA found in body fluid is listed in table 5-3. 
 
Table 5-3: Compiled version of miRNAs found commonly in two or more body fluids.     
VB = venous blood, MB = menstrual blood, and VF = vaginal fluid.  
 
 
 
 
 
 
 
MiRNA mature 5’ Body Fluid 
MiR-451a VB, MB, VF, saliva, and feces 
MiR-486 VB, MB, and feces 
MiR-26a-1, Mir-26a-2 VB, semen, and feces 
MiR-30d VB, semen, saliva and feces 
MiR-99a MB, VF, and semen 
MiR-205 MB, VB, and saliva 
MiR-21 All body fluids 
  
MiRNA mature 3’ Body Fluid 
MiR-101-1, miR-101-2, miR-22 All body fluids 
MiR-148a MB, VF, semen, saliva, and feces 
MiR-200a, 200b, and 200c MB, VF, and semen 
MiR-103a-1 VB, MB and feces 
MiR-203a MB, VF, saliva, and feces 
MiR-27b MB, VF, saliva, and semen 
MiR-92a-1, 92a-2 VB, and feces 
MiR-363 VB, feces, and semen 
 
 
 
116 
 
 
Table 5-4 Annotation results of each body fluid. Reporting top mature 5’ and 3’ miRNAs 
found abundant in each body fluid. The ones in bold are unique miRNAs, found among the top 
10-20 miRNAs in all body fluids. Unique miRNAs were found through a UNIX command. The 
count (not shown) of miRNA for each body fluid is listed in descending order.  
Body Fluid Top  mature 5’ miRNAs Top mature 3’ miRNAs 
Venous blood  miR-451a 
 let-7g  
 let-7i  
 miR-486-2  
 miR-486 
 miR-21  
 let-7f-2  
 let-7f-1  
 miR-191 
 miR-185 
 miR-20a 
 miR-30e 
 miR-26a-1 
 miR-26a-2 
 miR-30d 
 let-7a-2 
 let-7a-1 
 miR-144 
 miR-101-1  
 miR-101-2  
 miR-92a-1  
 miR-92a-2  
 miR-25  
 miR-22  
 miR-126  
 miR-103a-1  
 miR-103a-2  
 miR-363 
Menstrual blood  miR-21 
 miR-451a 
 miR-205 
 miR-99a 
 let-7f-2 
 let-7g 
 let-7f-1 
 let-7i 
 miR-486-2 
 miR-486 
 miR-146b 
 miR-203a 
 miR-148a 
 miR-200b 
 miR-27b 
 miR-22 
 miR-200c 
 miR-200a 
 miR-101-2 
 miR-101-1 
 miR-103a-1 
 miR-143 
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 miR-30a  miR-223 
Vaginal fluid  miR-21 
 miR-203b 
 miR-451a 
 miR-205 
 let-7b 
 miR-99a 
 let-7g 
 let-7i 
 miR-203a 
 miR-148a 
 miR-27b 
 miR-223 
 miR-22 
 miR-378a 
 miR-200c 
 miR-221 
 miR-101-2 
 miR-101-1 
 miR-200a 
 miR-200b 
Semen  miR-21 
 miR-10b 
 miR-99a 
 let-7b 
 miR-30a 
 let-7g 
 let-7f-1 
 let-7a-1 
 let-7a-3 
 let-7a-2 
 miR-26a-1 
 miR-30d 
 miR-26a-2 
 let-7c 
 miR-148a 
 miR-200b 
 miR-200a 
 miR-375 
 miR-200c 
 miR-151a 
 miR-363 
 miR-148b 
 miR-101-2 
 miR-101-1 
 miR-22 
 miR-27b 
 miR-141 
 miR-28 
 miR-320a 
Saliva  miR-21 
 miR-1246 
 miR-451a 
 miR-26a-2 
 miR-26a-1 
 miR-205 
 miR-191 
 let-7g 
 miR-148a 
 miR-223 
 miR-203a 
 miR-143 
 miR-27b 
 miR-101-2 
 miR-101-1 
 miR-140 
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 miR-30e 
 miR-26b 
 let-7i 
 let-7f-2 
 let-7f-1 
 miR-30d 
 miR-340 
 miR-23a 
 miR-25 
 miR-378a 
 miR-22 
 miR-374a 
 miR-125b-2 
 miR-345 
 let-7d 
 miR-125b-1 
 miR-181b-2 
Feces  miR-451a 
 miR-21 
 miR-486-2 
 miR-486 
 let-7i 
 let-7g 
 miR-191 
 let-7f-2 
 let-7f-1 
 miR-185 
 miR-144 
 miR-30d 
 miR-26a-1 
 miR-26a-2 
 miR-148a 
 miR-101-2 
 miR-144 
 miR-101-1 
 miR-25 
 miR-22 
 miR-140 
 miR-92a-1 
 miR-92a-2 
 miR-126 
 miR-103a-2 
 miR-103a-1 
 miR-203a 
 miR-363 
 miR-106b 
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Figure 5-3 A-L: Common mature 5’ and 3’miRNAs for each body fluid. MiRNA count 
indicates the number of times each miRNA occurred in a particular body fluid. The y-axis is listed 
as a logarithmic scale base 10, for better display of the small values. For each file per body fluid 
high count miRNAs were selected, common miRNAs were found through a UNIX command, and 
the data was further combined into one graph showing the pattern of how most abundant miRNAs 
varied per sample for each body fluid. A fixed miRNA count threshold, per file in each body fluid, 
was set differently, due to high variability in counts of miRNA.  
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5.8 Discussion: 
MiRNAs are small class of non-coding RNA that regulate protein levels or inhibition of 
mRNA post-transcriptionally. These non-coding RNA play an important role in cellular 
processes such as differentiation, transformation, cell replication and regeneration [81]. Due to 
their broad impact a significant interest in identifying miRNAs as biomarkers for diagnoses and 
therapeutic monitoring of diseases such as cancer, neurodegenerative disorders, heart disease and 
infection has developed. Next generation sequencing (NGS) technologies are being used to 
identify miRNAs from biological fluids, as sequencing RNA will allow for the profiling of all 
extracellular miRNAs both known and unknown at one time [82]. These small non-coding RNAs 
are found to be extremely stable in many harsh conditions such as boiling, low or high pH, 
chemical or ultraviolet treatment. Studies have suggested that reason behind miRNA’s 
exceptional stability even when treated with RNaseA is because they are not naked in nature and 
are encapsulated in exosomes or other microvesicles, making them highly stable and non-
degradable [83].  
 Inspired by the idea that miRNAs can serve as biomarkers for cancer, the aim of this 
research was to initially sequence RNA from venous blood, menstrual blood, vaginal fluid, 
semen, saliva and feces of healthy male and female volunteers. In the future comparison RNA 
sequence data from prostate cancer patient would identify any dysregulated miRNAs that might 
detect and stage prostate cancer. The Illumina-HiSeq technology platform was used to sequence 
the RNA and the data was analyzed under the CLC genomic software. Results of this analyses 
showed that venous blood was rich in miRNA, its annotation percentage was the best among all 
the body fluids. One study reported 42% annotation of miRNAs in blood while our analyses 
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produced 77% annotation [84].  Most of the miRNAs observed in the published study were also 
observed in our analyses. To name some they are: miR-451a, miR-191-5p, miR-486-5p and miR-
30d, miR-103a-3p, miR-92a-1, miR-92a-2, and miR-26a-5p. The following presents an overview 
of common miRNAs that were found in our analyses as well in the literature.  
MiR-451a and miR-144 
One study reported that miR-451a is heavily present in many body fluids, which was true 
for our analyses as well [84]. Except for semen, miR-451a was found in menstrual blood, vaginal 
fluid, saliva, and feces. MiR-144 is also found in venous blood and together with miR-451a, it is 
expressed under homeostatic condition, and is responsible for regulating erythroid development. 
In fact, another study reported that the loss of miR-144/451, causes instability in mice and 
increases their susceptibility to damage after being exposed to oxidant drugs. Depletion of miR-
451 has also caused anemia in zebrafish embryos [85].  
MiR-26a 
MiR-26a was observed in venous blood, semen, and feces. This miRNA has frequently 
been discovered in blood and studies have shown that it is commonly down regulated in 
nasopharyngeal carcinoma (NPC). This miRNA reduces the expression of enhancer of zeste 
homolog 2 (EZH2) oncogene in NPC cells, which inhibits cell growth, and cell-cycle 
progression by inducing G1 phase cell-cycle arrest; whereas, overexpression of the EZH2 
induces cell growth, and cell-cycle progression [86]. EZH2 is a mammalian histone 
methyltransferase that assists in epigenetic silencing of target genes and regulates the survival 
and metastasis of cancer. This gene acts as a co-activator for transcription factors such as the 
androgen receptor (AR). The AR plays a crucial role in prostate cancer progression and in order 
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to control this cancer, treatments often include inhibition of AR [87]. The correlation found 
between AR, EZH2 and miR-26 indicates that miR-26 can be used as a potential target for EZH2 
to control prostate cancer progression and metastasis.  
MiR-101-1, miR-101-2 
 MiR-101 was ubiquitous in all biological fluids. Studies have revealed that miR-101 also 
inhibits the expression of EZH2 gene in cancer cell lines. In human prostate tumors miR-101 
expression decreases during cancer progression leading to an increase in expression of EZH2, 
which concomitantly dysregulates epigenetic pathways, causing progression and metastasis of 
cancer cells. The loss of expression during cancer progression indicates that miR-101 is possibly 
a tumor suppressor [88]. Hence, restoration of miR-101 in prostate cancer cell lines may 
potentially target EZH2, enabling its expression to go down, and ultimately controlling cancer 
progression and metastasis.  
MiR-22 
MiR-22 is known as metastasis-inhibitor in ovarian cancer. A negative co-relation was 
observed between miR-22 and the metastatic behavior of ovarian cancer cells. Bioinformatic 
analyses have revealed that miR-22 maybe regulating pro-metastatic genes, which may explain 
the inhibitory effects miR-22 has on cell migration and invasion in ovarian cancer cells [89]. 
Similarly another study also showed a correlation between miR-22 and cell proliferation and the 
tumorigenicity of hepatocellular carcinoma (HCC). In the 160 paired HCC tissue samples, miR-
22 was found to be down-regulated in HCC, while histone deacetylase 4 (HDAC4) which is 
known to promote cancer growth was found to be up-regulated. It is possible that the loss of 
miR-22 contributed to the up-regulation of HDAC4, indicating that miR-22 might be targeting 
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HDAC4 [90]. Although, this miRNA may not have been studied in prostate cancer, but its 
presence in all the body fluids indicates that it is an important miRNA and its proposed effects 
on prostate cancer should be taken into consideration in the future.  
MiR-200a, -200b, -200c family, miR-103, and miR-92a 
The family of miR-200a, miR-200b, and miR-200c was observed in menstrual blood, 
vaginal fluid and semen. A study reported that elevated levels of the miR-200 family may 
correlate with serous epithelial ovarian cancer (SEOC). Where this family was found to be 
highly expressed in the SEOC relative to normal human ovarian epithelial cells. MiRs 103 and 
92a showed no change in expression across all ovarian cell lines. Exceptional high levels of the 
miR-200 family members may possibly serve as biomarkers for SEOC. Whereas, miR-103 and 
miR-92 can be used as normalizers for RT-qPCR analyses [91]. Since the miR-200 family was 
observed in three of our body fluid samples, their count was not as high as compared to other 
miRNAs found in these body fluids. Although, the count levels of these miRNAs were low in the 
body fluids, it is informative to know that elevated levels of the miR-200 family may point to 
signs of ovarian cancer and they can be used as biomarkers for this particular kind of cancer. 
Similarly, miR-103 and miR-92 were observed as top miRNAs in our venous blood and feces 
samples but as low count miRNAs in menstrual blood, vaginal fluid and semen, therefore, they 
can be used as normalizers when determining the levels of miR-200 family in the above 
mentioned body fluids.  
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Mir-21 
MiR-21 was another miRNA that was observed in all our body fluids. This small 
regulatory non-coding RNA, has been strongly conserved throughout evolution. It plays an 
important role in many biological functions and diseases such as development, cancer, 
cardiovascular diseases and inflammation. Expression of miR-21 in almost all types of cancer 
has been dysregulated, hence it has always been classified as an oncomiR. In particular this 
miRNA was found to be overexpressed in cancers such as lung, breast, stomach, prostate, colon 
and pancreas. Due to its consistent over-expression nature in cancers, this miRNA has also been 
proposed as a biomarker of malignancy in blood, sputum, cerebrospinal fluid, and feces. This 
miRNA has not been studied much in prostate cancer. However its involvement in tumor growth, 
invasion, metastasis, and cell proliferation indicates that it promotes apoptosis resistance, 
motility, and invasion in prostate cancer.  Although heart failure in mice due to inhibition of 
miR-21 has proven to be beneficial, more studies need to be conducted to ascertain the 
therapeutic benefits of removing or inhibiting miR-21in cancer [92, 93]. Since this miRNA has 
been strongly conserved evolutionarily, it has always been overexpressed in many cancers, 
including prostate, and was observed in all of our body fluids, this miRNA can be proposed as a 
potential biomarker for detecting signs of cancer in patients, in particular for prostate cancer in 
patients. 
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The presence of unique miRNAs in body fluids are as follows:  
MiR-20a 
MiR-20a was found unique in venous blood. The overexpression of miR-20a promotes 
proliferation and invasion by targeting amyloid precursor protein (APP) in human ovarian cancer 
cells [119]. One study screened 718 human miRNA markers in all body fluids using a microarray 
platform. The results indicated that several RT-qPCR confirmed miRNA markers appeared to be 
over-expressed in venous blood; among which four miRNAs, miR-20a, miR-106a, miR-185, and 
miR-144, were identified as blood markers, [120].  
MiR-146b 
MiR-146b was found unique in menstrual blood. A study reported that miR-146b is located on 
chromosome 10q24.3, and loss of this chromosome is frequently observed in gliomas. MiR-146b 
has been linked with the suppression of epidermal growth factor in human glioblastoma cell 
lines. In fact introduction of this miRNA in this cell line has been shown to decrease cell 
invasion, migration and phosphorylation of protein kinase B (AKT). These findings suggests that 
restoring miR-146b may be useful for treatment of invasive tumor [121].  
MiR-203b 
This miRNA was observed in the vaginal fluid. This is a skin specific miRNA that was found to 
be upregulated in psoriasis [122] and is involved in keratinocyte differentiation [123]. This 
miRNA has also been known to act as a novel tumor suppressor in esophageal cancer by down-
regulating the expression of small GTPase RAN and miR-21 [123].  
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MiR-10b 
MiR-10b was unique to semen, and one study reported that miR-10b was considered a semen 
marker [119]. Another study reported that miR-10b could be considered as a potential biomarker 
for breast cancer. Increased expression of miR-10b was observed in the lymphatic metastatic 
tissues, and could be directly assayed in the plasma to detect the lymph node status of breast 
cancer in patient [124].  
MiR-26b 
This miRNA was unique in saliva. Down-regulation of this miRNA has been linked to head and 
neck squamous cell carcinoma and oral squamous cell carcinoma [125]. Inhibition of miR-26b 
has also been known to affect pituitary tumor cell behavior through regulation of its direct target 
PTEN [126].  
MiR-144-5p 
MiR-144-5p was observed as unique in feces. A study reported that overexpression of this 
miRNA in feces suggested that it could be a potential candidate diagnostic marker for colorectal 
cancer detection. It was up-regulated in both feces samples and tissue samples from the CRC 
patients. This miRNA may be involved in cell death mechanisms, since it targets Apoptotic 
protease activating factor 1 (APAF1), a cytoplasmic protein that initiates apoptosis. The function 
of miR-144-5p or miR-144* is still unknown and further experimental analyses is needed to 
validate the actual function of this miRNA [127].  
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The annotation report for each of the body fluids 
The NGS analyses revealed a wide range of miRNAs present in each of the body fluids. 
The annotation results revealed that venous blood was indeed rich in miRNAs. Other body fluids 
were not as rich in miRNAs as venous blood. A study performed by Stephen et al, reported that 
semen contains a heterogeneous population of spermatozoa, contributing to a varied population 
of small RNAs. Their research was to assess whether RNAs, such as mRNAs or small-non-
coding-RNAs, delivered from mammalian spermatozoa played a functional role in embryo 
development. For this study, RNA sequencing was performed on Illumina’s GAII sequencer, and 
the reads were mapped against the human reference genome, Hg19. The results revealed that 
human spermatozoa contains multiple classes of small RNAs, in fact it mostly consists of 65% of 
repeat associated small RNAs and only 7% miRNAs [94]. Our deep sequencing analyses closely 
correlated with this study and revealed that semen consisted of ≈8% miRNAs. This shows that 
miRNAs are not abundant in semen, being present in only small amounts. Other body fluids such 
as menstrual blood, vaginal fluid, saliva and feces showed low annotation percentages for 
miRNAs. However, a slight correlation between our analyses and a study performed by Weber et 
al., was observed. This study demonstrated that through a global survey of miRNAs across 
various body fluids via RT-qPCR, 458 miRNAs were detected in saliva [10]. Our analyses 
detected 361 miRNAs in saliva. Although the methods to determine miRNAs in saliva were 
different between the two studies, the close proximity observed in the number indicates that 
saliva also might not be a very rich source of miRNAs.  
Menstrual blood, in particular, did not annotate (4.4%) as well as a former study 
indicated (60%) [96]. One reason behind poor annotation could be due to low quality scores 
observed for our sequences. NGS consists of a series of steps that uniquely contributes to the 
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overall quality of the data set. Sequencing quality metric can provide information about the 
accuracy of each step in the sequencing process, such as library preparation, base calling, and 
read alignment [108]. Base calling accuracy is measured by the Phred Quality score (Q score). 
The Q score indicates the probability that a given base is called incorrectly by the sequencer. Q 
scores are initially based on Sanger sequencing accuracy, and although certain NGS techniques 
may vary from Sanger sequencing, the process to generate Phred quality scoring largely remains 
the same. In particular, de novo NGS platforms such as the Illumina, their methods to generate 
Phred Q score are similar to that of Sanger sequencing methods. Q scores are logarithmically 
related to base calling error probabilities. For instance, a Q score of 30 to a base is equivalent to 
the probability of an incorrect base call of 1 in 1000 bp, which means the probability of a correct 
base call is 99.9%.  Similarly a Q score of 20 indicates the probability of an incorrect base call is 
1 in 100 bp, meaning every 100 bp sequencing read will likely contain an error, thus the 
probability of a correct base call reduces to 99%. Therefore a score of Q30 is considered a 
benchmark for quality in NGS [108]. The Q score for menstrual blood was Q20. The quality 
score was determined by fastqc software [109], which is a quality control application for fastq 
files. In general, fastq formatted files contain a quality value for each base, which says how 
confident the sequencer was that the base call generated was correct. This software takes in the 
fastq formatted file and runs a series of tests to generate a comprehensive quality score report. It 
basically shows anything that might be unusual about the sequence [109]. Low quality scores can 
increase false-positive base calls, which could in turn result in inaccurate conclusions when 
analyzing sequencing data or validating experiments. A Q score of 20 was observed for other 
body fluids i.e. vaginal fluid, saliva, and feces, as well, hence that could be one reason for low 
annotation observed for these body fluids.  
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Another reason for low annotation could due to genomic DNA, or bacterial 
contamination naturally found in menstrual blood, vaginal fluid, saliva, and feces. In general the 
human lower genital tract is constantly exposed to various microorganisms, which could infect 
the upper genital tract through migration. The normal microbial flora found in the vagina 
contains some gram negative bacteria that could infect the uterine wall after migrating from the 
vagina and thereby contaminate menstrual blood [110]. Other than bacterial contamination 
naturally found in these fluids, such contamination can also be encountered during sample 
collections. Improved purification steps and collections steps might be applied to avoid any sort 
of contamination in the future. For instance, it is recommended that immediately before 
collecting saliva, foods containing high sugar or caffeine should not be consumed, as they may 
lower saliva pH and increase bacterial growth. Any consumption of alcohol, nicotine, or over the 
counter prescription drug should be reported 12 hours in advance. The presence of any oral 
disease or injury should also be reported, a mouth should be rinsed at least 10 minutes before 
collecting saliva, to avoid diluting the samples [111]. Another effective method of collecting 
saliva is using the Oragene, it is a simple, painless procedure that requires the donor to spit into 
the collection device. After closing the device a solution is released from the cap to mix with the 
saliva. This solution stabilizes the DNA for long-term and prevents any bacterial contamination 
[112]. Many studies report collection of menstrual blood through a sterile swab, however these 
studies report different kits to extract RNA. For our analyses miRNeasy mini kit (Qiagen N.V., 
Venlo, The Netherlands) was used; however one study used the AllPrep DNA/RNA Micro kit 
(Qiagen, Dusseldorf, Germany). They modified the manufacturer’s protocol slightly and found 
an increased improvement in RNA extraction and protection from RNase. While genomic DNA 
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from menstrual blood samples was removed using Turbo DNA-free kit (Ambion, Austin, TX, 
USA) [113].  
In conclusion despite low annotation, miRNAs observed in menstrual blood correlated 
with miRNAs found by other published articles, such as miR-451a, miR-21, miR-22 [95]. In fact 
many other miRNAs observed in our body fluid samples also closely matched with other studies. 
Also, with the few selected miRNAs we were able to gain insights on miRNAs that could serve 
as biomarkers in prostate cancer, and some that could be used as normalizers when analyzing 
levels of particular miRNAs in body fluids. Overall, a wide range of miRNAs were discovered in 
the 6 biological fluids. To move this research further, miRNA expression levels will need to be 
analyzed in biological fluids from prostate cancer patients, to identify relevant biomarkers for 
disease validation and staging.  
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Chapter 6 
Conclusions 
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MicroRNAs are a novel class of small non-coding RNA that are thoroughly being studied 
in cancer, including prostate cancer. Malignant cells are dependent on dysregulated miRNAs for 
tumor progression or metastasis. Alterations to normal cellular behavior in cancer is caused by the 
up-regulation of oncogenes due to loss of tumor suppressor miRNAs or down-regulation of tumor 
suppressor genes due to gain to oncomiRs [114]. For better treatment options for cancer, 
dysregulated miRNAs are now currently being considered as potential therapeutic targets. It is 
proposed that by restoration of lost tumor suppressors miRNAs and/or the removal of gained 
oncomiRs can help mediate the tumor progression and metastasis of malignant cells [115].  
The majority of our laboratory work was performed with a weakly tumorigenic parental 
P69 cell line and its highly tumorigenic metastatic variant the M12 cell line. Using these models, 
a variety of dysregulated miRNAs were previously discovered. Out of a human panel of 736 
miRNAs, 231 miRNA were identified as oncomiRs which exhibited a ≥2 fold increase in 
expression, and 150 miRNAs were identified as tumor suppressors which exhibited a ≤ 0.5 fold 
decrease in expression, in the P69 vs. M12 cell lines. A combination of a few oncomiRs and tumor 
suppressors were selected for single-miR confirmatory analyses, where most of the miRNAs 
exhibited same fold differences, but others differed. MiR-147b was consistently classified as 
oncomiR, while miR-299-5p was seen as a tumor suppressor in the human panel analyses, while 
no value was detected for the single-miR analyses. Similar dysregulated patterns for miR-299-5p 
was observed in laser microdissected samples from prostate cancer patient tumor biopsies as well. 
To either identify mRNA targets for these miRNAs or confirm their identity, a more thorough 
research was performed.  
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In this thesis, multiple miRNAs were studied in greater depth to understand their role in 
our prostate cancer progression model. Along with performing in-vitro analyses, in silico analyses 
was also performed to determine all the miRNAs present in body fluids of normal healthy 
individuals. MiR screen analyses can only identify a few selected miRNAs in body fluids, however 
NGS analyses can identify all the miRNAs. It is essential to determine which miRNAs are 
normally found in body fluids attained from healthy people; so that in analyzing patients’ body 
fluids, the loss or gain of miRNAs can be diagnostic of disease.  
The second chapter consisted of isolating the best miR-17-3p site(s) within the 3’UTR of 
ErbB2 mRNA that contributed the most in reducing its expression. ErbB2 was one of the most up-
regulated proteins observed via RPMA analyses in the M12 cell line compared to its parental P69 
cell line. Three potential miR-17-3p sites, 44/576, 110/576, and 451/576, were predicted and 
luciferase assay was performed on each of the constructs in the M12+miR-17-3p cell line. The 
luciferase assay confirmed a direct binding of miR-17-3p to the ErbB2 and, that deletion of second 
site 110/576 contributed the most to the reduced luciferase activity.  
Another important miRNA studied for this thesis was miR-299-5p. This miRNA varied 
vastly in its nature, as for human panel analyses it expressed as a tumor suppressor, while in a 
couple of patient tumor biopsy samples it expressed as an oncomiR. Thus, it became important to 
study how this miRNA might contribute to prostate cancer progression. Through the luciferase 
assay, a loss in expression was observed for the OPN, thus it was confirmed that miR-299-5p can 
directly bind to osteopontin (OPN). OPN is present in all body fluids, and an increase in its 
expression has been linked to tumor invasion and metastasis in prostate [47]. To further confirm 
the direct binding, OPN sites were mutated and luciferase assays re-confirmed that miR-299-5p 
was directly targeting this mRNA. Thus, luciferase assay re-confirmed that miR-299-5p was 
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directly targeting this mRNA. Proliferation assay showed no change in growth upon restoration of 
miR-299-5p in the M12 cell line. However, migration and invasion assays for the most part 
revealed that miR-299-5p was acting like an oncomiR. Instead of seeing reduced invasion and 
migration an opposite behavior was observed. It is difficult to conclude from the conflicting data 
on miR-299-5p under which condition it acts as a tumor suppressor or as an oncomiR. It was felt 
that these results could be affected by the altered expression of only miR-299-5p, without the 
normal contribution of miR-299-3p, its miR-299 precursor partner. Therefore, a considerable 
amount of work remains to address the importance of miR-299-5p in prostate cancer.   
MiR-147b appears to function as an oncomiR in prostate cancer. It has been consistently 
overexpressed in every type of analyses performed to identify potential miRNAs driving prostate 
cancer. The significance of this miRNA has not been properly studied in many cancers; however, 
5 potential mRNA targets, COL4A2, ALDH5A1, NDUFA4, SDHD, and IER5, were identified for 
miR-147b in the literature for lung cancer [62]. The luciferase assay performed on these 5 mRNA 
constructs in the M12 cell line revealed a direct binding between miR-147b and the 3’UTR of 5 
mRNA targets. Most of these targets are mitochondrial enzymes that are essential for normal 
tricarboxylic acid cycle and ETC activity [116]. The luciferase assay validates a direct binding of 
miR-147b to these targets, and confirms that miR-147b alters normal mitochondrial function in 
cancer cells, which facilitates the progression of tumor.  
All miRNAs studied in this thesis are thought to promote tumor progression and enable 
metastasis. Prostate cancer being the second most fatal cancer for men in the U.S., requires new 
diagnostic methods or treatments to treat this disease. Identifying these potential miRNAs in 
prostate cancer has allowed us to determine a few of its potential therapeutic targets, that if blocked 
could help alleviate the progression of cancer. To better understand the nature of tumor progression 
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and driving forces behind its formation, NGS analyses was performed on normal body fluids from 
healthy individuals to determine the presence of abundant miRNAs. It is essential to first identify 
miRNAs normally present in body fluids as they will serve as biomarkers and act as positive 
controls against miRNAs observed in body fluids from prostate cancer patients.  
A total of 6 body fluids, venous blood, menstrual blood, vaginal fluid, semen, saliva, and feces 
were obtained from male and female volunteers. Illumina-HiSeq technology was used to sequence 
the RNA obtained from these body fluids. A bioinformatic tool CLC genomic software was used 
to analyze the data. The analyses revealed that venous blood contained more than 70% miRNAs 
while feces contained only 0.2%.  
Certain miRNAs that were uniquely identified for each body fluid were, miR-20a for 
venous blood, miR-146b for menstrual blood, miR-203b for vaginal fluid, miR-10b for semen, 
miR-26b for saliva, and miR-144-5p for feces. Among which miR-10b and miR-144-5p were 
being considered as potential biomarkers for semen and colorectal cancer respectively.  
Certain miRNAs that were ubiquitous to all body fluids were: miRs-21, -22, -101-1, and -
101-2. MiR-21 was being considered as a potential biomarker for cancers such as breast, prostate, 
and ovarian. Similarly, the family of miR-200 was observed in menstrual blood, vaginal fluid, and 
semen, and was being considered as biomarkers for ovarian cancer. While some miRNAs were 
present in all body fluids, some were missing in a couple of body fluids such as, miR-451a was 
missing in semen, miR-148a was missing in venous blood, miRs-92a-1 and 92a-2 were present 
only in venous blood and feces. MiR-451a is considered a regulator for erythroid development, 
while miR-92a/b are being considered potential normalizers for serum.  
 
 
 
142 
 
The research on identification of miRNAs in body fluids is currently ongoing, and to fully 
conclude the results, NGS analyses will have to be performed next on body fluids obtained from 
prostate cancer patients. This will help determine which miRNAs can be considered as biomarkers 
or normalizers in prostate cancer.  
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